Latest

Broadcom sinks 10%, Nvidia and AMD extend declines as the AI trade melts down

Chip giant Nvidia slid further into red territory on Friday along with the rest of the semiconductor sector.

finance.yahoo.com 11-20-26

SpaceX Sells $32 Billion of AI Chip Debt at Yields Topping 8%

SpaceX sold $32 billion of bonds to fund its purchase of artificial intelligence chips on Thursday, in a complicated and relatively high-yielding transaction that...

finance.yahoo.com 11-20-26

Apple's secret AI agent shows John Ternus is done sitting out the AI race

Apple's AI agent plans hit Meta and Anthropic stock before the job listing revealing its ambitions disappeared.

finance.yahoo.com 11-20-26

Sandisk stock begins trading at 8-for-1 split, shares sink

Sandisk shares began trading at an 8-for-1 split on Friday.

finance.yahoo.com 11-20-26

Bitcoin plunges below $60,000, on pace for its worst month since June 2022

Bitcoin plunged below $60,000 on Friday, deepening a November sell-off that is shaping up to be the cryptocurrency's worst monthly decline in more than...

finance.yahoo.com 11-20-26

Danaher Partners With Microsoft to Build AI-Connected Scientific Instruments Danaher (NYSE: DHR) announced a strategic partnership with Microsoft to develop

Danaher (NYSE: DHR) announced a strategic partnership with Microsoft to develop smart scientific instruments and a shared agentic AI platform designed to connect laboratory...

11-20-26

Merck’s Sac-TMT Meets Overall Survival Endpoint in Phase 3 Gastroesophageal Cancer Trial Merck (NYSE: MRK) said its Phase 3 TroFuse-015

Merck (NYSE: MRK) said its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary endpoint of overall survival in patients with locally advanced...

11-20-26

Johnson & Johnson Says Tremfya Improves Axial PsA Symptoms and MRI-Confirmed Inflammation Johnson & Johnson (NYSE: JNJ) reported positive Phase

Johnson & Johnson (NYSE: JNJ) reported positive Phase 4 STAR study results for Tremfya in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial...

11-20-26

TD Cowen Upgrades UnitedHealth to Buy, Raises Price Target to $455 TD Cowen upgraded UnitedHealth Group (NYSE: UNH) to Buy

TD Cowen upgraded UnitedHealth Group (NYSE: UNH) to Buy from Hold and raised its price target to $455 from $402. UnitedHealth shares are at...

11-20-26

KBW Raises Ryan Specialty Price Target to $55, Maintains Outperform Keefe, Bruyette & Woods raised its price target on Ryan

Keefe, Bruyette & Woods raised its price target on Ryan Specialty (NYSE: RYAN) to $55 from $49 while maintaining an Outperform rating. Ryan Specialty...

11-20-26

StoneX Cuts NetEase Price Target to $140, Maintains Buy Rating StoneX lowered its price target on NetEase (NASDAQ: NTES)

StoneX lowered its price target on NetEase (NASDAQ: NTES) to $140 from $158 while maintaining a Buy rating. NetEase shares are at $100.08, down...

11-20-26

Goldman Sachs Cuts NRG Energy Price Target to $149, Maintains Buy Rating Goldman Sachs lowered its price target on NRG

Goldman Sachs lowered its price target on NRG Energy (NYSE: NRG) to $149 from $167 while maintaining a Buy rating. NRG shares are at...

11-20-26

NYSE:PANW

Post Image
Palo Alto Networks to Acquire Applied Compute in $4.5 Billion AI Deal

Palo Alto Networks (NASDAQ: PANW) entered into a definitive agreement to acquire Applied Compute in an all-stock transaction valued at $4.5 billion, expanding its strategy beyond cybersecurity into secure enterprise AI infrastructure.

Applied Compute provides post-training and inference technology for open-weight AI models. Palo Alto Networks plans to combine the platform with its security capabilities so enterprises can train, adapt and deploy open-source and open-weight models securely across public cloud and sovereign environments.

The acquisition also brings Applied Compute’s AI research team into Palo Alto Networks. Co-founder and CEO Yash Patil is expected to become Co-Chief AI Officer after closing, while the team will help embed AI more broadly across Palo Alto’s products and proprietary models.

The deal strengthens Palo Alto Networks’ position at the intersection of cybersecurity and enterprise AI as companies increasingly deploy a mix of open and closed models. The transaction is subject to regulatory approval and other customary conditions and is expected to close in Palo Alto Networks’ fiscal third quarter of 2027.
Post Image
Palo Alto Networks Jumps 8% Premarket as Q1 Growth Accelerates and FY27 Guidance Is Raised

Palo Alto Networks (NASDAQ: PANW) shares jumped 8% in premarket trading after the cybersecurity company reported strong fiscal first-quarter growth and materially raised its full-year outlook.

Revenue rose 39% year over year to $3.44 billion, while Next-Generation Security ARR surged 66% to $9.73 billion. Remaining performance obligations increased 35% to $21.0 billion, and non-GAAP operating income climbed to $1.1 billion from $746 million. Non-GAAP EPS rose to $1.05 from $0.93.

Cash generation was also strong, with adjusted free cash flow reaching $1.9 billion and a 56.2% margin. Palo Alto also announced plans to acquire Applied Compute, a platform focused on post-training and inference for open-weight AI models, extending its strategy around secure enterprise AI.

The 8% premarket rally appears to reflect the combination of rapid NGS ARR growth, strong cash flow and a substantial guidance increase. Palo Alto now expects fiscal 2027 revenue of $14.52-$14.57 billion, NGS ARR of $11.48-$11.53 billion and non-GAAP EPS of $4.26-$4.30, reinforcing expectations that cybersecurity demand remains resilient as AI-related threats and enterprise adoption accelerate.
Post Image
Palo Alto Networks Urges Shareholders to Reject Tutanota Mini-Tender Offer

Palo Alto Networks (NASDAQ: PANW) advised shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to 250,000 shares of the cybersecurity company at $450 per share in cash.

The offer represents only about 0.03% of Palo Alto Networks’ outstanding common stock. The company said it does not endorse the offer and has no affiliation with Tutanota or the related tender documents.

A key concern is the offer’s pricing condition. Tutanota’s proposal requires Palo Alto Networks shares to close above $450 on the final trading day before expiration. Unless that condition is waived, shareholders accepting the offer would therefore receive a price below the prevailing market value.

Palo Alto Networks also noted that Tutanota can extend the offer for additional periods ranging from 45 to 180 days, potentially delaying payment. The offer is currently scheduled to expire at 5:00 p.m. ET on November 2, 2026, unless extended.

Because the offer seeks less than 5% of Palo Alto Networks’ outstanding shares, it is not subject to many of the disclosure and procedural protections that apply to larger tender offers under SEC rules. The SEC has previously warned investors that some mini-tender offers are structured below market prices and can catch shareholders who fail to compare the offer with current trading prices.

The announcement is primarily an investor-protection notice rather than a fundamental business development. Palo Alto Networks is encouraging shareholders to check current market quotations, consult their broker or financial adviser, and exercise caution before participating in the offer.
Post Image
Palo Alto Networks Stock Rises 5% as BTIG Raises Price Target and AI Security Momentum Builds

Palo Alto Networks shares rose 5% to $393.36 after BTIG Research raised its price target to $425 from $404 while maintaining a Buy rating.

The positive analyst action comes alongside growing investor interest in Palo Alto’s role in AI security. GuruFocus reported that the company joined NVIDIA’s AI agent safety initiative, which includes more than 100 organizations working on technologies designed to keep autonomous AI agents within defined operating limits.

Palo Alto is also building out its own AI security capabilities. Its Unit 42 offering uses models from OpenAI, Anthropic and others to continuously probe customer environments for vulnerabilities, while NVIDIA’s OpenShell and Sentry focus more on controlling and monitoring what AI agents can do at runtime (GuruFocus).

Broader probable reasons behind the stock’s strength include rising enterprise demand for AI security, stronger spending on cloud and network protection, and expectations that agentic AI will create new security requirements around identity, permissions, runtime controls and threat detection.

The 5% gain suggests the higher BTIG target and Palo Alto’s expanding presence in AI security are reinforcing confidence in the company’s long-term growth opportunity.
Post Image
Palo Alto Networks Launches AI-Powered Continuous Offensive Security Service With OpenAI and Anthropic Models

Palo Alto Networks launched Unit 42 Continuous Frontier AI Defense, a new agentic offensive security service that uses advanced models including OpenAI’s GPT-5.6-Cyber and Anthropic’s Claude Mythos 5 to continuously identify, validate and help remediate enterprise security exposures.

The service is designed to move beyond point-in-time assessments by continuously testing an organization’s environment as it changes. It combines a multi-model AI harness with Unit 42 threat intelligence and offensive security expertise to identify attack paths across web applications, APIs, cloud infrastructure, source-code repositories and network assets.

Palo Alto Networks said the system can also provide prioritized remediation guidance, code-level fixes and virtual patch recommendations. The company developed the approach over six months of internal testing and more than 100 customer engagements, supported by a $17 million R&D investment.

According to Palo Alto Networks, its Frontier AI Exposure Analysis identified exposures in 100% of assessed customers, with 37% of those exposures rated high or critical. The company also said many vulnerabilities in third-party applications had no known CVE, highlighting the potential value of continuous AI-driven testing.

Continuous Frontier AI Defense is available worldwide through annual subscriptions, with configurations varying according to the OpenAI, Anthropic and open-source models used.
Post Image
Palo Alto Networks Stock in Focus as Citi Downgrades Rating to Neutral

Palo Alto Networks (NASDAQ: PANW) received a more cautious analyst assessment after Citigroup downgraded the cybersecurity company from *Buy to Neutral*.

The downgrade comes with Palo Alto Networks trading at a premium valuation following strong investor enthusiasm around cybersecurity and artificial intelligence. While the company remains one of the leading players in enterprise cybersecurity, a Neutral rating can reflect a view that much of the expected growth and competitive strength is already incorporated into the share price.

Palo Alto Networks has built a broad security platform spanning network security, cloud security and security operations, positioning it strongly as enterprises consolidate cybersecurity spending around fewer strategic vendors. Its expanding use of AI across security products also provides exposure to continued growth in AI-driven threat detection and automation.

Citi’s move from Buy to Neutral therefore represents a moderation of its previous bullish stance rather than an outright bearish call, with valuation and the balance between future growth expectations and the current share price likely to remain important considerations for PANW investors.
Palo Alto Networks Stock Slips 1% Despite Strong Q4 as GAAP Loss and Slower FY2027 Growth Weigh

Palo Alto Networks (NASDAQ: PANW) shares fell about 1% in premarket trading Wednesday despite reporting strong fiscal fourth-quarter results, as investors weighed rapid cybersecurity growth against a GAAP loss and a significant expected deceleration in Next-Generation Security ARR growth.

Fourth-quarter revenue jumped 34% year over year to $3.41 billion, while Next-Generation Security ARR surged 63% to $9.10 billion. The company added nearly $1 billion of net new NGS ARR during the quarter, and remaining performance obligations increased 34% to $21.2 billion.

Profitability was more mixed. Non-GAAP operating income rose to $1.0 billion from $768 million a year earlier, while adjusted EPS increased to $1.02 from $0.95. However, Palo Alto Networks recorded a GAAP net loss of $282 million, or $0.35 per share, compared with net income of $254 million a year earlier. GAAP operating income also dropped to $172 million from $497 million.

Cash generation remained strong, with quarterly adjusted free cash flow reaching $1.3 billion and the full-year adjusted free cash flow margin at 38.4%.

The modest negative stock reaction may primarily reflect expectations embedded in Palo Alto Networks’ valuation and its FY2027 outlook. The company forecasts FY2027 revenue of $14.10 billion to $14.20 billion, representing 23%–24% growth, while NGS ARR is expected to reach $11.075 billion to $11.175 billion, representing 22%–23% growth. That implies a sharp normalization from the 63% NGS ARR growth reported in Q4.

Still, the underlying cybersecurity business remains strong. Palo Alto Networks expects Q1 FY2027 revenue growth of 33%–34% and NGS ARR growth of 63%, while management continues to target $20 billion in NGS ARR by FY2030. The company also acquired AI-native platform Console, extending its Cortex business into agentic enterprise security.

The roughly 1% premarket decline therefore appears less like a reaction to weak results and more like investor caution over slowing forward growth, GAAP profitability and high expectations following Palo Alto Networks’ rapid expansion in AI-driven cybersecurity.
Palo Alto Networks Launches Frontier AI Critical Defense Program to Counter AI-Driven Cyber Threats

Palo Alto Networks (NASDAQ: PANW) has launched its Frontier AI Critical Defense Program, bringing together major technology and infrastructure organizations to protect critical systems against vulnerabilities increasingly being discovered and potentially exploited using artificial intelligence.

The program includes collaborations with AI leaders OpenAI and Anthropic, alongside IBM, Red Hat and Microsoft. It also involves operational technology companies including Siemens, Mitsubishi and Axis Communications, as well as healthcare, energy, open-source and cybersecurity organizations.

AI Is Accelerating Vulnerability Discovery

Palo Alto Networks said it recently used Frontier AI models to identify more than 14,000 previously unknown vulnerabilities in open-source software. The company warned that similar technology could allow attackers to automate vulnerability discovery and dramatically shorten the time between finding and exploiting security weaknesses.

This presents a particular problem for critical infrastructure operators, where conventional software patches often require extensive safety testing and cannot be deployed immediately.

Palo Alto Networks aims to address this gap through "virtual patching." Its Frontier Virtual Patching technology can provide network-level protection against newly identified vulnerabilities before conventional software patches are developed, tested and installed.

The initiative expands Palo Alto Networks' position in AI-driven cybersecurity as both attackers and defenders increasingly use advanced AI models. By combining AI-based vulnerability discovery with network-level defenses and threat intelligence, the company is seeking to move cybersecurity from reactive patching toward proactive protection against emerging threats.
Palo Alto Networks (PANW) Stock Rises After Wells Fargo and BNP Paribas Raise Price Targets

Palo Alto Networks (NASDAQ: PANW) shares gained about 4.4% on Wednesday after receiving fresh bullish analyst support, with both Wells Fargo and BNP Paribas Exane raising their price targets while maintaining positive ratings on the cybersecurity leader.

The analyst actions reinforce Wall Street's confidence in Palo Alto Networks' long-term growth prospects as enterprises continue increasing investments in cybersecurity and AI-powered security platforms.

# Analysts See Further Upside

Wells Fargo raised its price target to $420 from $325 while reiterating its Overweight rating, reflecting greater confidence in the company's earnings growth and expanding platform strategy.

BNP Paribas also increased its price target to $380 from $330 while maintaining its Outperform rating, citing continued strength in the company's cybersecurity offerings and long-term market opportunity.

# Cybersecurity Demand Remains Strong

Palo Alto Networks continues to benefit from growing enterprise demand for integrated cybersecurity solutions as organizations consolidate vendors and strengthen defenses against increasingly sophisticated cyber threats.

The company's expanding AI-powered security capabilities and platform-based approach have helped drive customer adoption across network security, cloud security, and security operations.

# Why PANW Stock Is Rising Today

Investors welcomed several positive developments:

* Wells Fargo raised its price target to $420 from $325 and maintained an Overweight rating.
* BNP Paribas Exane increased its target to $380 from $330 and reiterated its Outperform rating.
* Wall Street continues to see strong long-term demand for enterprise cybersecurity solutions.
* AI-driven security products remain an important growth catalyst for the company.

The multiple price target increases reinforced investor confidence in Palo Alto Networks' growth strategy, helping lift the stock more than 4% during Wednesday's session.
Palo Alto Networks Stock Surges 8% as Arete Research Raises Price Target

Palo Alto Networks (NASDAQ: PANW) shares jumped more than 8% on Monday after Arete Research significantly increased its price target on the cybersecurity leader, reflecting growing confidence in the company's long-term growth outlook.

The firm maintained its Buy rating while raising its price target to $433 from $185, signaling a much more optimistic valuation as demand for enterprise cybersecurity solutions continues to strengthen.

The upgrade comes as organizations worldwide increase spending on cloud security, artificial intelligence-driven threat detection, and network protection amid a rapidly evolving cyber threat landscape. Palo Alto Networks remains one of the industry's leading providers, with investors expecting continued growth from its expanding platform strategy and subscription-based security offerings.

The stock also benefited from a broader rally in technology shares, as easing geopolitical tensions between the United States and Iran improved overall market sentiment and encouraged investors to rotate back into high-growth sectors.

At the time of writing, Palo Alto Networks shares were trading around $329, up approximately 8.4% during Monday's session, making the stock one of the strongest performers in the technology sector.
Video Thumbnail
11-19-26The Investor
Video Thumbnail
11-13-26The Investor
Video Thumbnail
09-18-26European Investor
Video Thumbnail
09-14-26WS Investor
Video Thumbnail
09-08-26The Investor

US

Stock market today: Dow, S&P 500, Nasdaq sink as Anthropic IPO fails to ease AI worries

Stocks are on track to post weekly losses after Nvidia earnings and Anthropic's IPO weren't enough for investors to shake off AI angst.

(finance.yahoo.com)
Post Image
U.S. Consumer Sentiment Improves as Inflation Expectations Fall Sharply

U.S. consumer sentiment improved in November, with the University of Michigan Consumer Sentiment Index rising to 51.5 from 48.0, slightly above the 51.0 consensus forecast.

Consumer expectations strengthened more clearly, increasing to 52.9 from 48.8 and exceeding the 50.9 forecast. The improvement suggests households became somewhat more optimistic about the economic outlook despite sentiment remaining at relatively weak absolute levels.

Inflation expectations provided the strongest positive signal. One-year inflation expectations fell to 3.7% from 4.7%, well below the 4.3% consensus estimate.

For markets, the combination is moderately supportive for risk assets. Better sentiment and expectations point to firmer consumer confidence, while the sharp drop in inflation expectations is dovish for the Federal Reserve and could put downward pressure on Treasury yields and the U.S. dollar.
Post Image
U.S. Manufacturing Weakens Sharply as Jobless Claims Rise Above Forecasts

The Philadelphia Fed Manufacturing Index fell to 6.3 in November, sharply below the 20.6 consensus estimate and down from 20.9 previously, signaling a substantial slowdown in regional manufacturing activity.

Labor-market data were also softer than expected. Initial jobless claims rose to 203,000, above the 198,000 forecast and 202,000 previously, while continuing claims increased to 1.763 million versus 1.710 million expected and 1.693 million in the prior reading.

One positive signal came from the Philadelphia Fed Employment Index, which increased to 11.6 from 9.1, indicating manufacturers in the region continued to add workers despite weaker overall activity.

For markets, the combination is moderately dovish for the Federal Reserve. The large manufacturing miss and higher continuing claims point to softer economic and labor-market momentum, which could put downward pressure on Treasury yields and the U.S. dollar while supporting rate-sensitive equities. However, the stronger Philly Fed employment component limits the extent of the dovish signal.
Post Image
Atlanta Fed GDPNow Estimate Slips to 3.2% for Q4

The Atlanta Fed’s GDPNow estimate for U.S. fourth-quarter economic growth fell to 3.2%, down from the previous 3.4% estimate and below the 3.4% consensus reading.

The revision still points to a solid pace of economic expansion, but it suggests slightly weaker momentum than previously estimated.
U.S. Housing Starts Rebound Sharply in October but Building Permits Disappoint

U.S. housing starts jumped 9.9% month over month in October, far above the 2.4% consensus estimate and reversing the previous month’s 7.0% decline.

The annualized pace of housing starts rose to 1.309 million, beating expectations of 1.250 million and up from 1.191 million previously.

Building permits were weaker, however, falling to 1.295 million compared with the 1.380 million forecast and 1.398 million in the prior month.

The data point to a strong rebound in current residential construction activity, but the softer permits figure suggests momentum may be less robust in the months ahead.
Post Image
U.S. Retail Sales Beat Forecasts While Industrial Production Falls

U.S. retail sales rose 0.2% month over month in October, above the 0.1% forecast but slowing sharply from the previous 0.8% increase. Core retail sales were stronger, rising 0.6% versus the 0.4% forecast, although also below the prior 1.1% gain.

Weekly ADP employment growth accelerated to 23,800 jobs from 19,800 previously, suggesting continued resilience in private-sector hiring.

Industrial production provided a weaker signal, falling 0.4% month over month compared with expectations for no change and a previous 0.7% increase. On an annual basis, production was up 2.15%, little changed from 2.14%.

Meanwhile, the Atlanta Fed’s GDPNow estimate for fourth-quarter growth edged down to 3.4% from 3.5%, pointing to still-solid economic momentum despite softer industrial activity.
Post Image
New York Manufacturing Index Falls to 7.8 in November, Missing Expectations

The New York Empire State Manufacturing Index fell to 7.8 in November, well below the 17.6 forecast.

The reading also declined sharply from 25.5 in the previous month, indicating a significant slowdown in manufacturing activity across New York state.

The index remained above zero, which still signals expansion, but the drop suggests growth momentum weakened considerably during the month.
Post Image
U.S. Stocks Fall as Nasdaq Drops 1.5% and S&P 500 Slides Nearly 1%

U.S. stocks traded lower, with technology shares leading the decline as the Nasdaq Composite fell 1.54% to 24,974.47.

The S&P 500 dropped 0.97% to 7,518.86, while the Dow Jones Industrial Average declined 0.45% to 52,059.91.

The sharper Nasdaq decline points to heavier selling pressure in technology and other growth-oriented stocks, while the Dow’s smaller loss suggests relative resilience among large-cap industrial and value names.

The broad weakness comes as investors reassess the outlook for interest rates, Nvidia scandal and inflation following fresh U.S. economic data, contributing to a more cautious tone across equity markets.
Post Image
U.S. Producer Prices Rise 0.3% in October, Below Headline Forecast

U.S. producer prices increased 0.3% month over month in October, slightly below the 0.4% forecast and sharply slower than the previous 1.4% increase.

Core producer prices, which exclude food and energy, also rose 0.3% during the month, matching expectations and easing from the prior 0.8% increase.

The data suggest upstream inflation pressures moderated significantly in October after the unusually strong rise in the previous month.
Post Image
S&P 500 Edges Higher as Energy and Communication Services Lead Gains

The S&P 500 was modestly higher in midday trading, rising about 0.17% to 7,632.36 as strength in energy and communication services offset weakness in technology and materials.

Energy was the strongest-performing sector, gaining 1.83%, followed by communication services at 1.00%. Utilities rose 0.64%, consumer staples gained 0.49%, consumer discretionary advanced 0.38% and health care added 0.36%.

The broader market initially traded lower after the open before rebounding sharply during the late morning session. The S&P 500 briefly approached the 7,650 level before giving back part of its gains and stabilizing near 7,630 around midday.

Defensive and cyclical sectors generally outperformed technology. Real estate slipped 0.02%, financials fell 0.04% and industrials declined 0.06%. Information technology was down 0.32%, while materials was the weakest sector with a 0.49% decline.

The mixed sector performance suggests investors were rotating away from some technology and materials names while maintaining exposure to energy, communication services and defensive sectors.

With the S&P 500 holding slightly positive despite weakness in several major sectors, the session reflects a relatively balanced market rather than a broad-based risk-on move.
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-16-26WS News
Video Thumbnail
11-15-26WS News
Video Thumbnail
11-13-26Global Finance News
Video Thumbnail
11-08-26WS News

S&P 500

Stock market today: Dow, S&P 500, Nasdaq sink as Anthropic IPO fails to ease AI worries

Stocks are on track to post weekly losses after Nvidia earnings and Anthropic's IPO weren't enough for investors to shake off AI angst.

(finance.yahoo.com)
Infleqtion Rises 1.9% After Hours on Record Revenue and 30-Logical-Qubit Milestone

Infleqtion (NYSE: INFQ) shares rose 1.9% in after-hours trading after the quantum technology company reported record third-quarter revenue and maintained its full-year outlook.

Revenue increased 25% year over year to $9.1 million, while nine-month revenue rose 57% to $32.6 million. Infleqtion reiterated its 2026 revenue guidance of at least $45.1 million.

The company also achieved its 2026 target of demonstrating 30 entangled logical qubits in a single computation and ended the quarter with $560 million in cash and securities and no debt. However, its GAAP operating loss widened to $34.5 million from $6.7 million a year earlier.

The after-hours gain appears to reflect investor enthusiasm around the company’s quantum computing milestone, growing backlog and customer activity, despite continued heavy operating losses.
Post Image
U.S. Stocks Fall as Nasdaq Drops 1.5% and S&P 500 Slides Nearly 1%

U.S. stocks traded lower, with technology shares leading the decline as the Nasdaq Composite fell 1.54% to 24,974.47.

The S&P 500 dropped 0.97% to 7,518.86, while the Dow Jones Industrial Average declined 0.45% to 52,059.91.

The sharper Nasdaq decline points to heavier selling pressure in technology and other growth-oriented stocks, while the Dow’s smaller loss suggests relative resilience among large-cap industrial and value names.

The broad weakness comes as investors reassess the outlook for interest rates, Nvidia scandal and inflation following fresh U.S. economic data, contributing to a more cautious tone across equity markets.
Post Image
S&P 500 Edges Higher as Energy and Communication Services Lead Gains

The S&P 500 was modestly higher in midday trading, rising about 0.17% to 7,632.36 as strength in energy and communication services offset weakness in technology and materials.

Energy was the strongest-performing sector, gaining 1.83%, followed by communication services at 1.00%. Utilities rose 0.64%, consumer staples gained 0.49%, consumer discretionary advanced 0.38% and health care added 0.36%.

The broader market initially traded lower after the open before rebounding sharply during the late morning session. The S&P 500 briefly approached the 7,650 level before giving back part of its gains and stabilizing near 7,630 around midday.

Defensive and cyclical sectors generally outperformed technology. Real estate slipped 0.02%, financials fell 0.04% and industrials declined 0.06%. Information technology was down 0.32%, while materials was the weakest sector with a 0.49% decline.

The mixed sector performance suggests investors were rotating away from some technology and materials names while maintaining exposure to energy, communication services and defensive sectors.

With the S&P 500 holding slightly positive despite weakness in several major sectors, the session reflects a relatively balanced market rather than a broad-based risk-on move.
Post Image
U.S. CPI Rises More Than Expected in October as Core Inflation Holds at 0.3%

U.S. consumer prices rose 0.4% month over month in October, above the 0.3% forecast but slowing from September’s 0.6% increase.

Core CPI, which excludes food and energy, increased 0.3%, also exceeding the 0.2% forecast and matching the previous month’s pace.

Separately, ADP’s weekly employment measure showed private payrolls increasing by 19,800, slightly above the previous reading of 19,500.

U.S. equities traded modestly lower following the data. The S&P 500 was down 0.19%, the Dow Jones Industrial Average fell 0.35%, and the Nasdaq declined 0.06%.

The hotter-than-expected headline and core CPI readings suggest underlying inflation pressures remain persistent, potentially reinforcing expectations that the Federal Reserve will remain cautious about further monetary-policy easing.
Post Image
U.S. Jobless Claims Fall to 189,000 as Tech Stocks Slide

U.S. initial jobless claims fell to 189,000, below the 197,000 forecast and down from 195,000 previously, pointing to continued resilience in the labor market.

Continuing jobless claims, however, increased to 1.718 million from 1.695 million, slightly above the 1.710 million forecast. The combination suggests layoffs remain low, while workers already unemployed may be taking somewhat longer to find new jobs.

U.S. equities traded mixed following the data. The Dow Jones Industrial Average rose about 0.54%, while the S&P 500 fell 0.32% and the Nasdaq declined 1.12%.

The stronger initial claims reading may reinforce expectations that the labor market remains relatively firm, potentially limiting the case for faster monetary easing. The heavier decline in the Nasdaq suggests rate-sensitive technology stocks were under greater pressure, while the Dow showed relative strength.
Post Image
U.S. Stock Futures Rally After Democratic Midterm Sweep as ADP Employment Matches Prior Month

U.S. stock futures moved sharply higher on Wednesday as investors digested the Democratic sweep of both chambers of Congress and a stronger-than-expected private-sector employment report.

Dow futures climbed about 2.1%, S&P 500 futures rose 1.1%, while Nasdaq futures gained 0.4%. The broader move followed confirmation that Democrats won control of both the House and Senate in the November 3 midterm elections, creating a divided government with Republican President Donald Trump.

Labor-market data also provided support. ADP reported that U.S. private payrolls increased by 86,000 in October, matching the previous month’s reading and exceeding the 67,000 forecast. The result points to continued hiring momentum, although employment growth remains relatively moderate.

The market reaction suggests investors are balancing two themes. The election outcome has increased expectations that large legislative changes may become more difficult, while the ADP report indicates the labor market has not weakened sharply. Together, those factors supported cyclical shares and helped push Dow futures substantially higher.

The Nasdaq’s smaller gain also reflects a more complicated post-election backdrop for technology stocks. Democratic victories have increased investor focus on possible tighter oversight of AI infrastructure and data-center development, particularly after election campaigns in several states highlighted concerns over energy use, utility costs and local opposition to new data centers.

Overall, the combination of greater political clarity and resilient employment data is supporting U.S. equities ahead of the opening bell. However, investors are likely to remain focused on how the new congressional balance may affect fiscal policy, AI regulation and future Federal Reserve decisions.
Post Image
U.S. Stocks Rise as Oil Plunges and ISM Manufacturing Beats Forecasts

U.S. stocks extended gains Monday as sharply lower oil prices eased inflation concerns and stronger-than-expected ISM manufacturing data supported confidence in the economy.

The Dow Jones rose 1.03% to 52,304.31, the Nasdaq gained 0.87% to 25,658.79, and the S&P 500 advanced 0.62% to 7,627.00.

Brent crude fell more than 6% to around $106.41 a barrel. The sharp decline in energy prices provides a favorable backdrop for equities by reducing concerns over fuel-driven inflation and potentially lowering costs for businesses and consumers.

Economic data also offered support. The ISM Manufacturing PMI increased to 55.5 in October, beating the 54.5 forecast and improving from 54.5 previously. The reading remained well above the 50 threshold, indicating continued expansion in U.S. manufacturing activity.

At the same time, the ISM Manufacturing Prices index eased to 75.2 from 77.9 and came in below the 77.2 forecast. Although input-price pressures remained elevated, the decline provided some reassurance on the inflation outlook. Manufacturing employment slipped slightly to 52.4 from 52.7 but remained in expansion territory.

Construction spending was the major weak point, falling 1.9% month over month in September compared with expectations for a 0.4% increase and a previous 2.0% gain.

Overall, the rise in U.S. indexes appears to reflect a combination of sharply lower oil prices, stronger manufacturing activity and some moderation in manufacturing price pressures. The weak construction spending figure limited the otherwise positive macro picture but was not enough to offset the broader improvement in investor sentiment.
Post Image
U.S. Stocks Trade Mixed as Wider Trade Deficit Offsets Inventory Growth

U.S. stocks were mixed after fresh economic data showed a wider-than-expected goods trade deficit alongside stronger retail inventory growth. The S&P 500 rose 0.15% and the Dow gained 0.27%, while the Nasdaq was nearly unchanged, down 0.01%.

The U.S. goods trade deficit widened to $134.90 billion in September, larger than the $130.40 billion consensus estimate and the previous $132.07 billion deficit. The deterioration suggests imports continued to outpace exports and could weigh on the trade component of third-quarter GDP calculations.

Retail inventories excluding autos increased 0.4% in September, accelerating from 0.1% previously. Higher inventories can provide some near-term support to GDP, although persistent inventory accumulation can become a negative signal if it reflects weaker-than-expected final demand.

Overall, the releases offered a mixed economic signal: stronger inventory accumulation was offset by a larger trade deficit, helping explain the relatively subdued reaction across major U.S. equity indexes.
Post Image
Wall Street Rises as Strong Consumer Confidence Offsets Mixed U.S. Economic Data

U.S. stocks moved higher Tuesday, with the Nasdaq gaining 1.19%, the S&P 500 rising 0.66% and the Dow Jones adding 0.14%, as investors digested a mixed batch of economic data.

Conference Board Consumer Confidence climbed to 91.7 in October, well above the 81.2 forecast and up from 84.2 previously. The stronger-than-expected reading pointed to improved household sentiment and provided the clearest positive signal from the day’s releases.

New home sales also came in better than expected at an annualized 676,000 in September, compared with the 651,000 forecast, although sales edged down from 680,000 previously.

Other indicators were softer. Building permits slipped to 1.398 million, slightly below the 1.400 million forecast and 1.403 million prior reading. Weekly ADP employment growth slowed to 16,800 from 18,500, suggesting some moderation in private-sector hiring.

Durable goods orders rose 1.8% in September, a sharp improvement from the prior 0.1% increase but slightly below the 2.0% consensus estimate.

Overall, the data presented a mixed economic picture, with stronger consumer confidence and housing demand offsetting softer employment and building activity. The stronger move in the Nasdaq suggests risk appetite remained relatively firm despite the uneven macro signals.
Video Thumbnail
11-19-26The Investor
Video Thumbnail
11-19-26The Investor
Video Thumbnail
11-17-26The Investor
Video Thumbnail
11-17-26The Investor
Video Thumbnail
11-10-26European Investor

NASDAQ:NVDA

Broadcom sinks 10%, Nvidia and AMD extend declines as the AI trade melts down

Chip giant Nvidia slid further into red territory on Friday along with the rest of the semiconductor sector.

(finance.yahoo.com)
Post Image
NVIDIA Rises 3% Premarket as Q3 Revenue Doubles and Vera Rubin Ramp Accelerates

NVIDIA (NASDAQ: NVDA) shares rose 3% in premarket trading after the company reported another quarter of exceptional AI-driven growth, with third-quarter revenue reaching $115.8 billion, up 103% year over year and 20% sequentially.

Data Center revenue climbed 110% year over year to $107.6 billion, while non-GAAP operating income more than doubled to $77.9 billion. Non-GAAP diluted EPS rose 111% to $2.68, and non-GAAP gross margin remained strong at 74.9%.

The company also began shipping Vera Rubin NVL72, describing it as the fastest product ramp in NVIDIA’s history, with deployments underway across major cloud providers including Google Cloud, Microsoft Azure, Oracle Cloud Infrastructure and CoreWeave. NVIDIA also highlighted broad adoption of Vera Rubin, Vera CPUs, networking and AI infrastructure across hyperscalers, AI labs and enterprise partners.

For the fourth quarter, NVIDIA expects revenue of about $130 billion, plus or minus 3%, while assuming no Data Center compute revenue from China. The premarket gain appears to reflect continued triple-digit Data Center growth, a strong Vera Rubin ramp and another step-up in quarterly revenue despite some expected gross-margin moderation.
Post Image
NVIDIA Creates Board Committee for National Security and Export Controls

NVIDIA (NASDAQ: NVDA) established a new board-level National Security and Export Control Oversight Committee to oversee the company’s national security policies, export control compliance and global trade risk management.

The committee will be chaired by director Suzanne Nora Johnson and will also include Stephen C. Neal and John O. Dabiri. NVIDIA’s National Security Team and Global Trade Compliance Team will report directly to the committee and to Interim CEO Colette Kress on day-to-day operations.

The committee will meet at least quarterly and use independent outside experts in law, national security and trade compliance.

The move strengthens NVIDIA’s governance around increasingly sensitive advanced-computing technologies and export controls, reflecting the company’s growing exposure to geopolitical and national-security scrutiny.
Post Image
IBM, Fermilab and NVIDIA Plan New Modular Quantum Computing Platform

IBM (NYSE: IBM), Fermilab and NVIDIA announced plans to develop a new co-design platform combining IBM quantum systems with NVIDIA DGX B200 infrastructure to advance modular, fault-tolerant quantum computing.

The collaboration will also integrate quantum processors more directly into Slurm through the vendor-neutral QRMI interface, allowing HPC centers to schedule QPUs alongside CPUs and GPUs using familiar workflows.

Separately, IBM, RIKEN and NVIDIA reported a quantum-classical simulation that achieved a 79-fold improvement in accuracy over earlier runs while studying a complex iron-sulfur molecule.

The initiative strengthens IBM’s strategy of embedding quantum computing more deeply into conventional supercomputing environments while developing architectures for larger future quantum systems.
Post Image
NVIDIA Expands Slurm Support to Integrate Quantum Processors Into Supercomputing

NVIDIA (NASDAQ: NVDA) announced an expansion of Slurm aimed at making quantum processors easier to integrate into traditional supercomputing environments, extending the company’s push into hybrid quantum-classical computing.

The new Slurm release allows quantum processing unit developers to create a standardized interface to their hardware that can be reused across supercomputing centers. The system builds on the QRMI and QDMI interfaces and is already being adopted by Alice & Bob, IBM, IQM, Pasqal, Quantinuum and MQSC.

Slurm 26.11 is expected to become available later in November.

The development addresses a major integration bottleneck in quantum computing. Previously, connecting a new QPU to a supercomputing center often required custom software work for each combination of hardware and facility. The expanded Slurm architecture is designed to let centers incorporate quantum processors into existing workload scheduling and resource-management systems.

NVIDIA said scientists will also be able to run hybrid applications developed with CUDA-Q while Slurm coordinates access to CPUs, GPUs and quantum processors.

The company simultaneously expanded its broader quantum-GPU platform at SC26. New capabilities include CUDA-Q QEC for quantum error-correction research, CUDA-Q Algorithms for reusable quantum application components and CUDA-Q Pulse for GPU-accelerated qubit control.

NVIDIA highlighted several early performance demonstrations, including Fermilab using CUDA-Q to complete studies in three weeks that would otherwise have taken five months. QunaSys also used 1,024 NVIDIA Hopper GPUs to simulate more than 300 million quantum operations, while NVIDIA researchers simulated 104 qubits under realistic noise conditions on the JUPITER supercomputer.

The announcement strengthens NVIDIA’s position as an infrastructure and software provider connecting classical accelerated computing with emerging quantum systems, rather than relying on any single quantum hardware architecture.

Nvidia CEO Huang resigns amid affair scandals, board names CFO Colette Kress interim CEO

Nvidia CEO Jensen Huang is resigning following reports that he had an affair with a fellow executive at the AI giant and after he admitted to having a separate affair with a woman who US intelligence officials believe is a Chinese spy.

(finance.yahoo.com)

Nvidia live updates: Jensen Huang resigns, CFO Colette Kress to serve as interim CEO

Follow along for live updates and reactions to reports of Nvidia CEO Jensen Huang's involvement in two extramarital affairs and exit from the company.

(finance.yahoo.com)

Nvidia reportedly preparing to oust CEO Huang after alleged affairs with spy, Nvidia exec

Embattled Nvidia (NVDA) CEO Jensen Huang was allegedly involved in a second extramarital affair.

(finance.yahoo.com)
Post Image
NVIDIA Expands Korea AI Strategy With Investments in Point2, Motif, RLWRLD and Upstage

NVIDIA announced new planned investments in Korean artificial intelligence startups, expanding its exposure across AI infrastructure, foundation models, enterprise software and robotics.

The company confirmed an investment in Point2 Technology and said additional investments are planned in Motif Technologies, RLWRLD and Upstage. The announcement came during the MSIT-NVIDIA AI Startup Partnership Forum in Seoul, hosted with Korea’s Ministry of Science and ICT.

Point2 develops radio-frequency interconnect technology designed to move data between chips and racks in AI factories, offering an alternative to conventional copper and optical connections. Motif Technologies develops foundation models for AI agents, while RLWRLD is building robotics foundation models for humanoid and industrial robots performing complex physical tasks.

Upstage focuses on enterprise AI, including its Solar language models and document AI tools for extracting information and automating business workflows.

The investments broaden NVIDIA’s engagement across the full AI stack, from data-center infrastructure to software and physical AI. They also deepen the company’s relationship with Korea’s technology ecosystem, where more than 1,000 startups already participate in the NVIDIA Inception program.

The initiative reinforces NVIDIA’s strategy of supporting companies that could expand demand for AI computing infrastructure while accelerating development of agentic AI, robotics and next-generation AI factories.
Post Image
NVIDIA Says Vera CPU Delivers Faster AI Agent Performance With Higher Energy Efficiency

NVIDIA (NASDAQ: NVDA) said its Vera CPU can improve both AI agent performance and energy efficiency, targeting data centers increasingly constrained by power availability as agentic AI workloads expand.

According to NVIDIA, Vera enables 1.6 times more AI agents per watt than the fastest x86 CPU while delivering industry-leading agent speed. Compared with the most energy-efficient x86 processor tested, Vera delivered roughly twice the agent speed while maintaining strong power efficiency.

The company highlighted early performance results from several partners. Perplexity reported agentic coding workloads running 1.5 times faster on Vera than traditional CPUs, while DeepInfra achieved up to 2.2 times the speed of its best x86 processor in agent orchestration workloads.

Other tests showed ClickHouse scaling nearly linearly across 176 cores, while Daytona brought 1,000 AI-agent sandboxes online in 10.8 seconds compared with 88.4 seconds using x86 infrastructure. Modal reported up to twice the sandbox throughput per core.

The results reinforce NVIDIA’s push beyond GPUs into CPUs and full-stack AI infrastructure, as data center operators increasingly seek to maximize AI workloads per watt while supporting growing numbers of autonomous agents.
Video Thumbnail
11-20-26European Investor
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-18-26WS News
Video Thumbnail
11-17-26The Investor
Video Thumbnail
11-17-26The Investor

NYSE:MRK

Merck’s Sac-TMT Meets Overall Survival Endpoint in Phase 3 Gastroesophageal Cancer Trial

Merck (NYSE: MRK) said its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary endpoint of overall survival in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior lines of systemic therapy.

Sac-TMT produced a statistically significant and clinically meaningful improvement in overall survival versus physician’s choice of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Results were generally consistent across subgroups regardless of TROP2 expression status. However, the drug did not meet the secondary endpoint of progression-free survival.

The study enrolled 473 patients and marks the second positive Phase 3 readout from Merck’s global TroFuse development program. Sac-TMT is being evaluated across 18 ongoing Phase 3 trials in multiple tumor types, including gastric, breast, bladder, lung, ovarian and endometrial cancers.

The result is an important clinical catalyst for Merck’s oncology pipeline because sac-TMT is the first TROP2-directed antibody-drug conjugate to demonstrate an overall survival benefit in a global Phase 3 study in this patient population. Merck plans to present the data at an upcoming medical meeting and discuss them with regulatory authorities.
Merck Partners With Isomorphic Labs to Use AI in Oncology Drug Discovery

Merck (NYSE: MRK) entered a strategic research collaboration with Isomorphic Labs to discover small-molecule drug candidates against an oncology target, combining Merck’s proprietary data and drug-development expertise with Isomorphic Labs’ AI-based drug design platform.

Under the agreement, Isomorphic Labs will use its IsoDDE drug design engine and selected Merck data sets to make in silico predictions and design potential molecules. Merck will take responsibility for preclinical and clinical development, manufacturing and commercialization of any products that emerge from the collaboration.

Isomorphic Labs will receive an upfront payment and may earn additional research, development, regulatory and commercial milestone payments, as well as tiered royalties on future net sales. The company also has an option to co-fund development in exchange for higher royalties. Financial terms were not disclosed.

The partnership expands Merck’s use of AI in early-stage drug discovery and could help shorten molecule-design cycles by combining computational modeling with proprietary experimental data. However, the collaboration remains at the research stage, so any financial contribution would depend on successful candidate discovery, development and regulatory progress.
Merck Reports Positive Phase 2b Results for Efinopegdutide in MASH

Merck (NYSE: MRK) reported positive Phase 2b results for efinopegdutide, an investigational once-weekly GLP-1/glucagon receptor co-agonist being developed for adults with metabolic dysfunction-associated steatohepatitis, or MASH, and stage F2-F3 fibrosis.

The study met its primary endpoint, with MASH resolution without worsening of fibrosis achieved by 56%, 63% and 61% of patients receiving the 4 mg, 7 mg and 10 mg doses, respectively, compared with 13% for placebo at Week 52.

Efinopegdutide also showed improvement on the key secondary fibrosis endpoint. At least a one-stage improvement in fibrosis without worsening of steatohepatitis was seen in 43% of patients on 4 mg, 52% on 7 mg and 34% on 10 mg, versus 21% with placebo.

The safety profile was generally consistent with semaglutide, with gastrointestinal events including nausea, diarrhea and vomiting among the most common adverse effects. Discontinuation rates due to adverse events were 3%, 4% and 11% across the three efinopegdutide dose groups.

The Phase 2b trial enrolled 386 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis. Efinopegdutide has also received FDA Fast Track designation for the treatment of MASH.

The results strengthen Merck’s cardiometabolic pipeline by showing both disease-resolution and fibrosis benefits, although the program remains investigational and will require further development before any potential regulatory approval.
Merck’s Tulisokibart Meets Key Endpoints in Phase 2b Hidradenitis Suppurativa Study

Merck reported positive Phase 2b results for tulisokibart in patients with moderate to severe hidradenitis suppurativa, marking what the company described as the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology.

The study met its primary endpoint at week 16. HiSCR50 was achieved by 72% of patients receiving the high-dose regimen and 64% of those receiving the medium dose, compared with 35% for placebo. The low-dose group showed a 52% response rate in an exploratory analysis.

Key secondary measures also favored tulisokibart. HiSCR75 was reached by 41% of high-dose and 40% of medium-dose patients versus 15% with placebo, while quality-of-life scores also improved numerically in the higher-dose groups.

Safety was broadly comparable with placebo. Serious adverse events were infrequent, and no serious or opportunistic infections were reported.

Merck said the data will support advancement of tulisokibart into Phase 3 development for hidradenitis suppurativa. The drug is also being studied across several other immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, rheumatoid arthritis and psoriatic arthritis.
Merck Licenses SciBrunch’s KRAS G12D Cancer Drug Candidate in Deal Worth Up to $2.13 Billion

Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor targeting one of the most common cancer-driving mutations.

Under the agreement, Merck gains worldwide rights to develop, manufacture and commercialize SPR2015. SciBrunch will receive $400 million upfront and could earn additional development, commercialization and other milestone payments, bringing the total potential value of the deal to $2.13 billion.

SPR2015 is designed to selectively inhibit KRAS G12D, a mutation found across several major cancers, including pancreatic, colorectal and lung tumors. Preclinical data presented at the 2026 AACR Annual Meeting showed nanomolar antiproliferative activity in KRAS G12D-mutant cell lines and antitumor activity across multiple xenograft models.

The deal expands Merck’s precision oncology pipeline and gives the company another targeted approach beyond its established immuno-oncology franchise. Merck said the asset complements its growing portfolio of precision-targeted cancer candidates.

Merck will record a $400 million pre-tax charge related to the transaction in the third quarter of 2026, equal to about $0.13 per share on both a GAAP and non-GAAP basis.
FDA Updates Merck’s WINREVAIR Label With HYPERION Pulmonary Hypertension Data

Merck said the U.S. Food and Drug Administration approved an update to the label for WINREVAIR to include efficacy and safety data from the Phase 3 HYPERION trial in adults recently diagnosed with pulmonary arterial hypertension.

HYPERION enrolled patients diagnosed within the previous 12 months who were at intermediate to high risk of disease progression. Adding WINREVAIR to background therapy reduced the risk of clinical worsening events by 76% compared with placebo, with a hazard ratio of 0.24. A first clinical worsening event occurred in 10.6% of WINREVAIR-treated patients versus 36.9% of those receiving placebo.

The updated label provides additional evidence for using WINREVAIR earlier in the treatment pathway, rather than only later in the disease course. Most patients in HYPERION were already receiving double or triple background therapy, and the treatment effect was consistent across prespecified subgroups.

The FDA update also adds safety information from HYPERION. The most common adverse reactions included epistaxis, telangiectasia and increased hemoglobin, while treatment discontinuation due to adverse events occurred in 3% of WINREVAIR patients.

WINREVAIR is already approved for adults with pulmonary arterial hypertension to improve exercise capacity and functional class and reduce the risk of clinical worsening events. The new label strengthens Merck’s case for broader and earlier use of the drug in PAH care.
Merck’s KEYTRUDA QLEX Approved in Japan for All KEYTRUDA Indications

Merck said Japan’s Ministry of Health, Labor and Welfare approved KEYTRUDA QLEX for subcutaneous administration across all indications already approved in the country for intravenous KEYTRUDA.

In Japan, the product will be marketed under the planned name KEYJECT. It can be administered by a healthcare provider in about one minute every three weeks or two minutes every six weeks, making it the first and only subcutaneous immune checkpoint inhibitor available in Japan with administration as short as one minute.

The approval was supported by the Phase 3 MK-3475A-D77 study comparing subcutaneous KEYJECT with intravenous KEYTRUDA, both given every six weeks with chemotherapy in previously untreated metastatic non-small cell lung cancer. The study showed comparable pembrolizumab exposure, while response rates were 45% with KEYJECT plus chemotherapy and 42% with KEYTRUDA plus chemotherapy. No notable differences in progression-free or overall survival were observed.

Merck said the subcutaneous formulation could give patients and healthcare providers greater flexibility by allowing treatment in settings ranging from infusion centers to physician offices and community clinics.

KEYTRUDA QLEX is already approved in the U.S. for the same solid-tumor indications as KEYTRUDA, while subcutaneous pembrolizumab was approved in Europe in 2025.
Merck Wins Positive EU CHMP Opinion for KEYTRUDA-Padcev Bladder Cancer Regimen

Merck said the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer.

The recommendation covers use before surgery as neoadjuvant therapy and continued treatment after radical cystectomy as adjuvant therapy. A European Commission decision is expected by the fourth quarter of 2026. If approved, the combination would become the first PD-1 inhibitor plus antibody-drug conjugate regimen in the EU for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility.

The CHMP opinion is based on the Phase 3 KEYNOTE-B15 trial. In cisplatin-eligible patients, KEYTRUDA plus Padcev reduced the risk of an event-free survival event by 47% versus neoadjuvant chemotherapy and surgery. The regimen also reduced the risk of death by 35% and produced a pathologic complete response rate of 55.8%, compared with 32.5% in the control group.

The combination is already approved in the U.S. for muscle-invasive bladder cancer regardless of cisplatin eligibility, while the EU previously approved it for cisplatin-ineligible patients.

The latest recommendation could broaden Merck’s position in earlier-stage bladder cancer and further expand KEYTRUDA’s role beyond advanced disease.
Merck Stock Rises 2.7% as Argus and Wolfe Research Raise Price Targets

Merck & Co. (NYSE: MRK) shares rose about 2.7% on Tuesday as two Wall Street firms raised their price targets on the pharmaceutical company while maintaining bullish ratings.

Argus analyst Jasper Hellweg raised the firm's price target on Merck to $170 from $145 while maintaining a Buy rating. Wolfe Research analyst Alexandria Hammond was even more bullish, increasing the firm's target to $180 from $155 and maintaining an Outperform rating.

With Merck trading around $154.73, the new targets imply upside of approximately 10% and 16%, respectively.

## Why the Rating Reports Are Positive for Merck

The simultaneous target increases from two firms signal improving expectations for Merck's earnings and valuation.

Merck remains one of the world's largest pharmaceutical companies, with a strong oncology franchise led by Keytruda and a broader pipeline designed to diversify growth over the longer term. The company's position in oncology and continued investment in new medicines remain central to its growth outlook.

Tuesday's 2.7% gain appears to reflect the positive analyst sentiment, with both firms seeing additional upside even after the stock's recent performance.
Moderna Soars 100%, Merck Jumps 10% After Landmark Phase 3 Cancer Vaccine Results

Moderna shares surged about 100% on Wednesday, while Merck climbed roughly 10%, after the companies announced positive Phase 3 results for their personalized mRNA cancer therapy intismeran autogene in combination with Merck’s blockbuster immunotherapy KEYTRUDA.

The INTerpath-001 trial met both its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. The combination produced statistically significant and clinically meaningful improvements compared with KEYTRUDA alone.

A Major Milestone for Moderna’s mRNA Platform

The results are particularly significant for Moderna because they represent the first positive Phase 3 readout for an individualized neoantigen therapy and the first positive Phase 3 study for an mRNA-based cancer therapy. The treatment is individually manufactured using mutations identified from each patient's tumor, with the resulting mRNA therapy designed to train the immune system to recognize and attack cancer cells.

That breakthrough likely explains the much larger reaction in Moderna shares. The results potentially validate the use of Moderna's mRNA technology beyond infectious-disease vaccines and provide important clinical validation for its oncology pipeline.

The companies also said no new safety signals were observed. They plan to present detailed data at an upcoming international medical meeting and share the results with regulatory authorities, opening the path toward potential filing submissions.

Merck Gains as KEYTRUDA Franchise Could Expand

For Merck, the results strengthen the long-term position of KEYTRUDA, its cornerstone cancer therapy. The combination is the first regimen to demonstrate statistically significant and clinically meaningful improvements in both recurrence-free and distant metastasis-free survival compared with KEYTRUDA alone in this adjuvant melanoma population.

Earlier Phase 2b data had already provided encouraging evidence: at five-year follow-up, the combination showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared with KEYTRUDA alone.

The companies are now studying intismeran across a broader oncology program encompassing nine Phase 2 and Phase 3 trials, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma.

With Moderna up around 100% and Merck gaining about 10%, the market reaction reflects more than a single successful melanoma trial. Investors appear to be pricing in the possibility that personalized mRNA cancer therapies could become a new treatment platform, with potentially much broader applications if ongoing trials in other tumor types are successful.
Video Thumbnail
10-26-26Global Finance News
Video Thumbnail
09-10-26WS News
Video Thumbnail
08-20-26WS Investor
Video Thumbnail
08-19-26WS News
Video Thumbnail
08-04-26European Investor

NASDAQ:INTU

Post Image
Intuit Falls 8.5% as Softer Q2 Growth Outlook and Mailchimp Sale Overshadow Strong Q1

Intuit (NASDAQ: INTU) shares fell 8.5% after the company reported first-quarter results above guidance but issued a more moderate second-quarter growth outlook and announced plans to sell Mailchimp.

Fiscal first-quarter revenue increased 12% to $4.4 billion, while non-GAAP operating income rose 46% to $1.0 billion and adjusted EPS increased 56% to $2.91. Global Business Solutions revenue grew 15%, including 20% growth in the Online Ecosystem, while Consumer revenue increased 7%.

Intuit also agreed to sell Mailchimp to Bending Spoons for approximately $3.68 billion, including $3.31 billion in cash and $368 million in Bending Spoons stock. Mailchimp revenue declined 1% in the quarter, and Intuit said the divestiture will sharpen its focus on AI-native business tools and lead-to-cash capabilities.

The 8.5% decline appears to reflect concern over near-term growth rather than the Q1 results themselves. Intuit expects second-quarter revenue growth of only 6%-7%, while full-year revenue guidance now calls for 8%-9% growth and Credit Karma growth of 3%-7%. Although the company reiterated full-year earnings guidance and plans to use Mailchimp sale proceeds for share repurchases, investors appear focused on the slower top-line trajectory.
Post Image
Intuit Reaffirms Fiscal 2027 Outlook as Investor Day Highlights AI-Driven Growth Strategy

Intuit reaffirmed its first-quarter and full-year fiscal 2027 guidance Thursday as the financial software company used its Investor Day to highlight its long-term growth strategy and expanding use of artificial intelligence across its platform.

For fiscal 2027, Intuit continues to expect revenue of $23.28 billion to $23.51 billion, representing growth of 9% to 10%. GAAP operating income is projected at $7.41 billion to $7.49 billion, while diluted GAAP EPS is expected between $20.12 and $20.36.

The company also maintained first-quarter guidance for revenue of $4.29 billion to $4.31 billion, up about 11% year over year. Non-GAAP diluted EPS is expected between $2.44 and $2.48.

Management said Intuit is focusing on what it calls an AI-driven expert platform that combines proprietary financial data, domain-specific AI models and human expertise. The company said its strategy is aimed at scaling major growth initiatives and accelerating new-customer acquisition across products including QuickBooks, TurboTax, Credit Karma and Mailchimp.

For investors, the unchanged outlook provides continuity while the Investor Day shifts attention toward Intuit’s ability to use AI to improve automation, financial intelligence and customer engagement across its ecosystem.
Intuit Stock Rises 2% as RBC Reiterates Outperform Rating

Intuit shares rose 2% to $318.91 on Friday as RBC Capital Markets reiterated its Outperform rating on the financial software company.

RBC analyst Rishi Jaluria maintained a $385 price target on Intuit. The target represents potential upside of approximately 21% from the stock’s current price.

The reiterated positive rating signals RBC remains constructive on Intuit’s outlook despite the stock trading well below the firm’s price objective.

Investor attention remains focused on Intuit’s growth across its financial technology and business software platforms, as well as the company’s efforts to expand AI-powered capabilities across its product portfolio.
Intuit Stock Sinks 12% as FY2027 Growth Outlook Signals Sharp Slowdown

Intuit (NASDAQ: INTU) shares fell about 12% in premarket trading Wednesday despite reporting solid fiscal 2026 results, as investors focused on a significant slowdown in projected revenue growth for fiscal 2027 and weakness at Mailchimp and TurboTax.

Intuit finished fiscal 2026 with revenue rising 14% to $21.4 billion. GAAP operating income increased 20% to $5.9 billion, while GAAP EPS climbed 20% to $16.46. Fourth-quarter revenue also grew 14% to $4.4 billion.

Why Is INTU Stock Falling?

The primary concern appears to be the FY2027 outlook. Intuit expects total revenue of $23.28 billion to $23.51 billion, representing growth of just 9%-10%. That marks a noticeable deceleration from the 14% growth delivered in FY2026.

Several individual businesses also point to slower growth. TurboTax revenue is expected to increase only 2%-3% in FY2027, while the broader Consumer segment is projected to grow 4%-6%.

Mailchimp is an even clearer weak spot. Intuit expects Mailchimp revenue to range from a 1% decline to flat growth in FY2027. The company is also separating Mailchimp from Global Business Solutions and will report it as a standalone segment beginning this fiscal year.

Underlying TurboTax customer trends add to the caution. Total U.S. TurboTax units declined 2% in FY2026 to 39 million, including a 2% decline in online units and a 7% drop in desktop units.

AI Growth Remains a Long-Term Catalyst

There were still significant positives. Intuit said its strategic "Big Bets" grew 34% in FY2026 and generated 30% of total revenue, while management continues to position the company as an AI-driven financial platform.

QuickBooks Online Accounting revenue grew 23% for the year, Credit Karma increased 20%, and TurboTax Live jumped 37%, reaching 53% of total TurboTax revenue.

Intuit also expects strong FY2027 earnings growth, including GAAP EPS growth of 22%-24%, and increased its quarterly dividend by 15%.

Still, the 12% premarket selloff suggests investors are prioritizing the expected slowdown in top-line growth, particularly the weak Mailchimp outlook and modest TurboTax growth, over Intuit's continued margin expansion and AI-driven long-term strategy.
Intuit Stock Rises 3.9% as Deutsche Bank Sets $425 Price Target

Intuit (NASDAQ: INTU) shares are up about 3.9% after Deutsche Bank initiated a $425 price target on the financial software company, adding a positive analyst catalyst for the stock.

The $425 target compares with Intuit's current share price of $364.22, implying approximately 17% upside.

Intuit holds a leading position in financial technology and business software through platforms including TurboTax, QuickBooks, Credit Karma and Mailchimp. Its large base of consumers and small-business customers provides substantial recurring revenue, while the company is increasingly integrating artificial intelligence and automation across its products.

The analyst action comes as investors continue to focus on Intuit's ability to use AI to automate accounting, tax preparation and financial management. The company's established ecosystem and extensive financial data could give it a strong competitive position as AI adoption accelerates across the fintech and enterprise software sectors.

Intuit's 3.9% gain suggests the new $425 price target is contributing to positive investor sentiment, with the implied upside reinforcing expectations for continued growth in its core financial software businesses.
Intuit Stock Falls 2.4% as Mizuho Cuts Price Target to $430

Intuit (NASDAQ: INTU) shares fell about 2.4% on Monday after Mizuho lowered its price target on the financial software company, adding pressure to the stock despite maintaining a positive rating.

Mizuho analyst Siti Panigrahi reduced the firm’s price target on Intuit to $430 from $500 while keeping an Outperform rating. With INTU trading around $337.26 in the rating report, the revised target still implies approximately 28% upside.

The price-target reduction likely reflects a more cautious assessment of Intuit’s near-term growth and valuation rather than a fundamental change in the analyst’s longer-term investment thesis. The maintained Outperform rating suggests Mizuho continues to see attractive upside potential despite lowering its expectations.

Intuit remains a major player in financial software through platforms including QuickBooks, TurboTax, Credit Karma and Mailchimp. The company has increasingly positioned artificial intelligence as a key part of its strategy, using AI-driven tools to automate accounting, tax preparation and financial decision-making for consumers and small businesses.

Monday’s 2.4% decline indicates investors are focusing on the sizable 14% reduction in Mizuho’s price target. However, the retained Outperform rating and $430 target suggest the brokerage remains constructive on Intuit’s longer-term prospects.
Intuit Expands AI-Powered Finance Tools Across QuickBooks and Enterprise Suite

Intuit (NASDAQ: INTU) is expanding its AI capabilities across QuickBooks Online Advanced and Intuit Enterprise Suite, strengthening its push into the mid-market financial software and ERP sector.

The company introduced Intuit Intelligence Chat, which allows CFOs and controllers to ask questions about financial performance, identify anomalies, generate reports and initiate workflows using natural language. The system can also recommend actions while maintaining human approval and auditability.

QuickBooks Online Advanced is adding AI-powered bookkeeping through Books Upkeep, which automatically processes high-confidence transactions and directs exceptions to users. New business intelligence tools also provide real-time KPI monitoring and conversational forecasting.

Meanwhile, Intuit Enterprise Suite is expanding further into the ERP market with AI-assisted multi-entity accounting, multi-currency support and deeper industry-specific capabilities for construction, manufacturing and nonprofits.

The expansion strengthens Intuit's position in AI-powered financial software as the company moves beyond traditional small-business accounting toward larger and more complex organizations. The new capabilities are rolling out to U.S. customers across QuickBooks Online Advanced and Intuit Enterprise Suite.
Intuit Plunges 13% in Premarket as Massive Layoffs and Restructuring Charges Overshadow Strong Results

Intuit tumbled 13% in premarket trading today despite reporting a genuinely strong third quarter and raising full-year guidance, as investors focused almost entirely on a jarring announcement buried in the capital allocation section — a 17% reduction in its full-time workforce alongside $300 million to $340 million in restructuring charges.

The underlying financial results were hard to fault. Total revenue grew 10% to $8.6 billion. Consumer revenue rose 8% to $5.3 billion, with TurboTax up 7% to $4.4 billion and Credit Karma accelerating 15% to $631 million on strength in personal loans, auto insurance and home loans. Global Business Solutions grew 15% to $3.3 billion, with Online Ecosystem revenue up 19% and QuickBooks Online Accounting up 22%. GAAP diluted EPS rose 11% to $11.09 and non-GAAP diluted EPS grew 10% to $12.80. The company also received board approval for a new $8 billion share repurchase authorization and raised its quarterly dividend 15% to $1.20 per share.

Full-year guidance was raised across every metric, with total revenue now expected to grow 13% to 14% to approximately $21.36 billion, and non-GAAP diluted EPS growth of approximately 18% to $23.80 to $23.85.

None of that mattered to the market this morning. The workforce reduction announcement — framed as a move to simplify organizational structure and become a faster, leaner, more focused company — immediately raised questions about the nature of the restructuring. Coming from a company that has been vocal about its AI-driven expert platform strategy, the layoffs could be interpreted as AI beginning to displace human roles within Intuit itself, most notably in TurboTax Live where human experts assist customers. TurboTax Live revenue is expected to grow 36% to $2.8 billion for the full year, representing 53% of total TurboTax revenue — a business built on human expertise that may now be facing internal automation pressure.

The $300 million to $340 million in restructuring charges will largely hit Q4, depressing GAAP EPS for the quarter to just $0.73 to $0.79 despite healthy underlying business momentum.

The 13% premarket drop reflects a market unsettled by the scale and timing of the workforce reduction — a signal that even the companies building AI tools are not immune to the disruption those tools create.
Intuit Achieves FedNow Certification to Enable Instant Payments

Intuit Inc. announced it has completed certification for the Federal Reserve’s FedNow Service, allowing it to expand real-time payment capabilities for businesses.

The integration enables instant money movement across Intuit’s platform, helping small and mid-sized businesses get paid faster, manage cash flow more efficiently, and access funds immediately. Key features include instantly payable invoices, real-time payroll, and on-demand bill payments.

By connecting to FedNow, Intuit can partner with financial institutions to process instant transactions, reducing reliance on slower traditional systems such as ACH.

The company said the move supports its broader strategy to unify payments, payroll, and banking services, improving financial decision-making and operational efficiency for its customers.
Business Wire

SaaSpocalypse Revisited: Three Fears, Three Answers

Explore the SaaSpocalypse Revisited: Three fears addressed and the future of SaaS stocks after recent market fluctuations.

(thesmartinvestor.com.sg)
Video Thumbnail
11-20-26European Investor
Video Thumbnail
08-26-26Global Finance News
Video Thumbnail
08-25-26WS Investor
Video Thumbnail
08-24-26European Investor

NYSE:JNJ

Post Image
Johnson & Johnson Says Tremfya Improves Axial PsA Symptoms and MRI-Confirmed Inflammation

Johnson & Johnson (NYSE: JNJ) reported positive Phase 4 STAR study results for Tremfya in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial involvement. The study met its primary and major secondary endpoints, showing significant improvement in axial symptoms and reductions in sacroiliac joint inflammation versus placebo.

At Week 24, BASDAI scores improved by 3.3 points with Tremfya every four weeks and 2.9 points with every-eight-week dosing, compared with 2.1 points for placebo. Tremfya also produced greater improvement on ASDAS-CRP, another measure of axial disease activity.

MRI results were particularly notable. Sacroiliac joint inflammation scores fell by 7.1 points with every-four-week dosing and 5.2 points with every-eight-week dosing, versus a 2.4-point reduction with placebo, representing more than twice the improvement seen with placebo. No new safety signals were identified.

The results strengthen Tremfya’s clinical profile in psoriatic arthritis by adding prospective MRI-based evidence in axial disease, an area with limited dedicated trial data. The findings could support broader physician confidence in the drug’s use across different PsA manifestations, although the every-four-week regimen evaluated in the study is not currently approved in the U.S.
Post Image
Johnson & Johnson Begins Commercial Launch of OTTAVA Surgical Robot With First U.S. Installation

Johnson & Johnson (NYSE: JNJ) announced the first commercial installation of its OTTAVA robotic surgical system at Memorial Hermann-Texas Medical Center in Houston, marking the start of the platform’s U.S. commercial rollout.

OTTAVA received FDA De Novo authorization in July 2026 for ten general surgery procedures, including gastric bypass, gastrectomy, cholecystectomy and appendectomy. The system integrates four robotic arms into a standard-sized surgical table and is designed to reduce operating-room space constraints and streamline surgical workflows.

Memorial Hermann previously participated in the clinical program supporting OTTAVA’s regulatory authorization, giving Johnson & Johnson an experienced initial customer as it moves from development into commercial use. The company plans to expand the launch to additional selected U.S. hospitals while evaluating the platform for further indications.

The installation is strategically important for Johnson & Johnson’s MedTech business because it establishes OTTAVA as a commercial competitor in the fast-growing robotic surgery market. Near-term financial impact is likely limited during the early-access phase, but successful adoption could create a new long-term growth platform across robotic systems, instruments and digital surgical services.
Post Image
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Adding Phase 3 Eye-Disease Drug

Johnson & Johnson (NYSE: JNJ) agreed to acquire clinical-stage biotech Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline with a late-stage treatment for serious retinal diseases.

The transaction also includes potential regulatory and commercial milestone payments of up to approximately $1.125 billion.

Ollin’s lead asset, OLN324, is a Phase 3 investigational bispecific antibody targeting both VEGF and Ang2, two important pathways involved in retinal vascular disease. The therapy is being developed for wet age-related macular degeneration and diabetic macular edema, conditions that collectively affect more than 40 million people worldwide.

Johnson & Johnson said OLN324’s high Ang2 potency and smaller antibody format could improve control of retinal fluid and potentially allow longer intervals between treatments.

The company is also entering into a separate development funding agreement with Blackstone Life Sciences. Blackstone will provide $750 million over multiple years to fully fund Phase 3 development of OLN324. In return, Blackstone will be eligible for certain regulatory and sales milestone payments as well as single-digit royalties.

The acquisition is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.

Strategically, the deal strengthens Johnson & Johnson’s ophthalmology portfolio and adds a late-stage asset with potential exposure to two large retinal-disease markets. It also limits near-term development funding requirements through the separate Blackstone financing arrangement.
Post Image
Johnson & Johnson Reports Second Positive Phase 3 Study for CAPLYTA in Bipolar Mania

Johnson & Johnson (NYSE: JNJ) reported positive results from a second pivotal Phase 3 study of CAPLYTA in adults with bipolar I disorder experiencing manic episodes, strengthening the case for a planned U.S. FDA submission in the indication.

In Study 452, once-daily CAPLYTA 42 mg produced a statistically significant improvement in manic symptoms versus placebo after three weeks. The drug achieved a 3.7-point greater reduction on the Young Mania Rating Scale, with benefits appearing as early as Day 3 and continuing through Week 3.

Clinical response rates were also materially higher. At Week 3, 43.9% of CAPLYTA-treated patients achieved at least a 50% improvement in YMRS scores compared with 23.7% of patients receiving placebo. CAPLYTA also significantly improved overall illness severity on the CGI-S scale.

Safety was consistent with CAPLYTA’s established profile, with dizziness, dry mouth and somnolence or sedation among the most common treatment-related adverse events.

Together with the previously positive Study 451, the results provide two successful pivotal Phase 3 trials supporting Johnson & Johnson’s planned regulatory submission for bipolar mania. CAPLYTA is already approved for bipolar depression, schizophrenia and as adjunctive therapy for major depressive disorder, but is not currently approved for manic episodes associated with bipolar I disorder.
Post Image
Johnson & Johnson Reports 73% PSA Response With Experimental Prostate Cancer Combination

Johnson & Johnson (NYSE: JNJ) reported encouraging Phase 1 results for an experimental prostate cancer immunotherapy combination, with 73% of patients at the recommended regimen achieving at least a 50% reduction in prostate-specific antigen.

The regimen combines pasritamig, a KLK2-targeting bispecific antibody, with JNJ-9401, a PSMA-targeting bispecific designed to provide a complementary T-cell activation signal. Among 15 patients treated at the recommended dose, 11 achieved PSA reductions of at least 50%, while seven, or 47%, achieved reductions of at least 90%.

The responses also appeared durable in this early dataset. All seven patients with PSA reductions of at least 90% remained on treatment for more than six months without disease progression. Four patients achieved undetectable PSA levels.

Safety was also encouraging at the recommended regimen. No Grade 3 or higher treatment-related adverse events, dose-limiting toxicities, treatment-related discontinuations or deaths were reported. Cytokine release syndrome occurred in three patients, but all cases were mild Grade 1 events.

The combination is now being evaluated in the Phase 3 KLK2-comPAS study in metastatic castration-resistant prostate cancer, representing an important next step for Johnson & Johnson’s prostate cancer pipeline.

While the Phase 1 results are based on a small patient group and require confirmation in larger studies, the depth of PSA responses and early safety profile suggest the dual-targeted approach could become a meaningful new option in advanced prostate cancer.
Post Image
Johnson & Johnson Wins FDA Approval for Rybrevant Faspro in Advanced Head and Neck Cancer

Johnson & Johnson (NYSE: JNJ) said the U.S. FDA granted accelerated approval to Rybrevant Faspro as a single-agent treatment for certain adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum chemotherapy and an anti-PD-(L)1 therapy.

The approval is the first for a dual EGFR- and MET-targeted therapy in this treatment setting and marks Rybrevant Faspro’s first indication beyond non-small cell lung cancer. The therapy is administered as a subcutaneous injection.

FDA clearance was supported by the Phase 1b/2 OrigAMI-4 study, where the confirmed overall response rate was 42%, including complete responses in 15% of patients. Among responders, 56% maintained their response for more than six months.

The indication excludes HPV-associated oropharyngeal squamous cell carcinoma, and continued approval may depend on confirmation of clinical benefit in the ongoing Phase 3 OrigAMI-5 study.

The approval broadens Johnson & Johnson’s oncology franchise by extending amivantamab into another difficult-to-treat solid tumor and could increase the commercial opportunity for the Rybrevant platform beyond lung cancer.
Post Image
Johnson & Johnson Reports Strong VARIPULSE and OMNYPULSE Data in Atrial Fibrillation

Johnson & Johnson (NYSE: JNJ) reported new clinical data for two pulsed field ablation platforms at the APHRS 2026 meeting, highlighting strong acute procedural results for VARIPULSE Pro and encouraging 12-month outcomes for the investigational OMNYPULSE system.

In the VARIPURE study, which included 225 patients across 19 European centers, the VARIPULSE Pro Platform achieved 100% acute procedural success. The study reported one primary adverse event, representing a 0.4% rate, with no reported stroke, coronary spasm, acute kidney injury or death. Mean ablation time was 17.9 minutes, and a single-catheter mapping-and-ablation workflow was used in 88.9% of cases.

VARIPULSE Pro is currently available in Europe, Japan and certain other international markets, but is not approved in the United States.

Separately, the Omny-IRE study evaluated 136 patients with symptomatic paroxysmal atrial fibrillation. At 12 months, 82.5% of patients remained free from documented atrial fibrillation, atrial flutter or atrial tachycardia recurrence under stringent monitoring, rising to 90.1% under standard-of-care monitoring. The reported adverse-event rate was 2.9%, and all safety events were resolved.

Patients treated with OMNYPULSE also showed a 25.5-point mean improvement in the Atrial Fibrillation Effect on Quality-of-Life score, along with reductions in antiarrhythmic medication use and cardiovascular-related hospitalizations. OMNYPULSE remains investigational and is not approved or available for sale.

Johnson & Johnson also cited real-world database results suggesting lower long-term atrial-fibrillation-related acute-care utilization with its CARTO 3 mapping system compared with EnSite, with patients treated using EnSite showing a 31% higher risk of AF/AFL/AT-related inpatient readmission or emergency-room visits in that analysis.

The findings add clinical evidence across Johnson & Johnson’s electrophysiology portfolio and support the company’s broader push into pulsed field ablation, although the OMNYPULSE results remain investigational and VARIPULSE Pro is not yet approved in the U.S.
Post Image
Johnson & Johnson Falls 4.8% Despite Q3 Beat as MedTech Weakness and 2027 EPS Dilution Weigh on Shares

Johnson & Johnson (NYSE: JNJ) shares fell about 4.8% even as the company reported third-quarter operational sales growth of 6%, ahead of analyst expectations, and raised its full-year 2026 guidance.

Innovative Medicine remained the main growth engine, with operational sales up 7.9%. Oncology grew about 17%, while RYBREVANT sales increased 64% and TREMFYA surged 68%. SPRAVATO also delivered 36% growth, highlighting continued momentum across several of J&J’s key pharmaceutical franchises.

The weaker area was MedTech, where operational sales increased just 2.5% and management acknowledged that performance fell short of expectations. J&J specifically pointed to Cardiovascular and Surgery outside the U.S. as areas needing improvement, while ABIOMED continued to face pressure from physician selectivity.

J&J raised its 2026 operational sales growth outlook to 6.7%-7.1%, representing about $100.7 billion at the midpoint. Reported sales are expected to reach roughly $101.2 billion at the midpoint. Adjusted reported EPS guidance was tightened to $11.05-$11.15.

However, investors may be focusing more heavily on the company’s 2027 earnings outlook. Management said the Firefly Bio acquisition and Sail Biomedicines collaboration are expected to reduce full-year 2027 adjusted EPS by a combined $1.36 per share, a meaningful near-term earnings headwind despite their longer-term pipeline potential.

The quarter also included the previously announced $5.5 billion agreement to resolve ovarian talc litigation, subject to participation by at least 95% of remaining claimants. The charge is reflected in third-quarter GAAP results.

The 4.8% decline therefore appears to reflect a combination of softer-than-expected MedTech performance, especially in Cardiovascular and Surgery, and concern over substantial acquisition-related EPS dilution expected in 2027, outweighing the strong pharmaceutical growth and improved 2026 guidance.
Post Image
Johnson & Johnson Reports Two-Year ICOTYDE Data Showing Durable Skin Clearance in Plaque Psoriasis

Johnson & Johnson reported new two-year Phase 3 data for ICOTYDE, or icotrokinra, showing sustained skin clearance in patients with plaque psoriasis affecting difficult-to-treat areas including the scalp, genitals, hands and feet.

In the ICONIC-TOTAL study, 70% of ICOTYDE-treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Complete clearance rates at Week 112 reached 60% for scalp psoriasis, 89% for genital psoriasis and 63% for psoriasis affecting the hands or feet.

Nail psoriasis also continued to improve over time, with the average improvement in the modified Nail Psoriasis Severity Index reaching 71% at Week 112.

Safety findings through two years remained consistent with ICOTYDE’s established safety profile, with no new safety signals identified.

ICOTYDE is a once-daily oral peptide designed to block the IL-23 receptor. It is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and patients aged 12 and older who meet treatment criteria, and is also approved in Europe, Japan and China.

The long-term results strengthen Johnson & Johnson’s case for ICOTYDE as an oral systemic treatment option, particularly for patients with psoriasis affecting sensitive or highly visible areas where treatment can be especially challenging.
Post Image
Johnson & Johnson Highlights Two-Year IMAAVY Data Showing Sustained Disease Control in gMG

Johnson & Johnson reported new two-year data for IMAAVY in generalized myasthenia gravis, showing sustained improvements in daily function and muscle strength among adolescents treated in the Phase 2/3 Vibrance-MG study.

At Week 108, patients with available data maintained a mean 2.88-point improvement in the MG-ADL score and an 8.25-point improvement in the QMG score from baseline. Corticosteroid use also declined, with three of six adolescents taking steroids at study entry reducing their dose and one discontinuing treatment after two years. No new safety signals were identified.

Johnson & Johnson also presented retrospective real-world data from healthcare professionals treating adults with anti-AChR or anti-MuSK antibody-positive gMG. Fluctuating symptom control was cited as the most common reason for stopping a previous advanced therapy.

Among 97 patients who switched to IMAAVY, 73.2% were reported as “much improved” or “very much improved.” Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.

IMAAVY is an FcRn blocker approved for adults and patients aged 12 and older with antibody-positive generalized myasthenia gravis. The new findings add longer-term evidence supporting sustained disease control and reduced corticosteroid dependence.
Video Thumbnail
05-02-26WS News
Video Thumbnail
12-30-25European Investor
Video Thumbnail
10-14-25European Investor
Video Thumbnail
10-04-25European Investor
Video Thumbnail
04-15-25WS News

NASDAQ:AMD

Broadcom sinks 10%, Nvidia and AMD extend declines as the AI trade melts down

Chip giant Nvidia slid further into red territory on Friday along with the rest of the semiconductor sector.

(finance.yahoo.com)
Post Image
AMD-Powered Lux Supercomputer Opens to Researchers at Oak Ridge

AMD (NASDAQ: AMD), the U.S. Department of Energy and HPE have opened the Lux supercomputer at Oak Ridge National Laboratory to scientific users, making it the first dedicated U.S. AI Factory supporting the DOE’s Genesis Mission.

Lux combines AMD EPYC processors, Instinct MI355X GPUs, Pensando networking and ROCm software in an HPE-built system that integrates AI with high-performance modeling and simulation. The system ranks 14th on the latest TOP500 list.

Initial Genesis Mission projects include AI-assisted fusion power plant design, materials and advanced manufacturing research, and Earth-system prediction for water availability and river conditions.

The deployment strengthens AMD’s position in government and scientific AI infrastructure while extending its longstanding Oak Ridge partnership beyond the Frontier supercomputer into dedicated AI-driven research capacity.
Post Image
AMD Completes World Labs Acquisition, Adds Fei-Fei Li as Chief Scientist

Advanced Micro Devices (NASDAQ: AMD) completed its acquisition of World Labs, expanding its AI capabilities beyond hardware and software infrastructure into foundational model research.

World Labs develops AI models capable of creating and simulating interactive 3D environments, along with technologies focused on robotic learning and simulation. AMD said the acquired team will work directly with its engineers to help shape future hardware, software and systems for the company’s open AI ecosystem.

As part of the transaction, World Labs founder Dr. Fei-Fei Li will join AMD as executive vice president and chief scientist, reporting directly to CEO Lisa Su.

The acquisition reflects AMD’s strategy of increasingly co-designing AI infrastructure with the models and workloads that will run on it. Su said closer optimization between compute platforms and AI models will be important in developing infrastructure for the next generation of advanced AI systems.

World Labs will continue its foundational model research while collaborating with AMD engineering teams to translate emerging AI model requirements into future compute architectures and infrastructure products.

The deal could broaden AMD’s competitive positioning in AI by giving the company direct access to advanced model research, particularly in spatial intelligence, robotics and 3D simulation. It also strengthens AMD’s effort to build a more vertically integrated AI platform spanning CPUs, GPUs, networking, software and model development.

‘No family dinners’: AMD boss Lisa Su is Jensen Huang’s cousin — with Nvidia on the ropes, is this her time to shine?

Jensen Huang is officially out at Nvidia — but AMD, Nvidia's top competitor, is being led by his talented cousin.

(finance.yahoo.com)
Post Image
AMD EPYC Powers Google Cloud TPU 8tx as Confidential AI Infrastructure Expands

AMD (NASDAQ: AMD) announced that its 5th Gen EPYC processors are powering the host infrastructure for Google Cloud TPU 8tx, the first cloud TPU system to support hardware-enforced confidential computing.

The collaboration combines AMD EPYC CPUs with Google’s eighth-generation TPU architecture to support inference, fine-tuning and reinforcement learning workloads while protecting sensitive AI data and models during use.

AMD said EPYC processors handle workload orchestration, data preparation and high-throughput communication with TPU accelerators. The system uses AMD Secure Encrypted Virtualization technology to help keep prompts, model weights and intermediate data encrypted in CPU memory and during transfers between the host and accelerators.

The deployment expands AMD’s role as a host CPU provider for accelerated AI systems. The company said EPYC processors are now used as host CPUs across more than 10 leading hyperscalers and frontier AI labs, spanning systems built around AMD Instinct GPUs, NVIDIA GPUs and custom AI accelerator ASICs.

AMD and Google Cloud have already collaborated across multiple generations of EPYC-based virtual machines and confidential computing services. TPU 8tx extends that relationship into secure AI acceleration.

The announcement strengthens AMD’s position in AI infrastructure beyond GPUs, highlighting EPYC CPUs as a core component of increasingly specialized AI systems where security, memory bandwidth, I/O performance and accelerator coordination are critical.
Post Image
AMD Jumps 8% Premarket as Data Center Revenue Nearly Doubles and Q4 Outlook Accelerates

AMD (NASDAQ: AMD) shares rose about 8% in premarket trading after the company reported record third-quarter 2026 revenue, nearly doubled Data Center sales and issued a strong fourth-quarter outlook.

Third-quarter revenue increased 45% year over year to a record $13.4 billion and rose 16% sequentially. Non-GAAP EPS climbed 74% to $2.09, while non-GAAP operating income increased 75% to $3.92 billion.

Data Center was the clear growth engine. Segment revenue surged 97% year over year to a record $8.5 billion, driven by strong demand for EPYC processors and the launch of Instinct MI450 Series GPUs. AMD said demand for Instinct and EPYC products continues to strengthen as production of Helios systems and 6th Gen EPYC “Venice” processors scales.

Operating leverage improved sharply alongside the revenue acceleration. GAAP operating margin expanded to 21% from 14% a year earlier, while non-GAAP operating margin increased five percentage points to 29%. Non-GAAP gross margin was 56%, up from 54% a year earlier.

Performance outside Data Center was more mixed. Client revenue grew 7% to $2.9 billion, while Gaming revenue fell 40% to $773 million due to weaker semi-custom and graphics sales. Embedded revenue increased 29% to $1.1 billion.

AMD also highlighted broader adoption of its AI infrastructure, with Anthropic, Meta, Microsoft, OpenAI and Oracle Cloud Infrastructure running workloads on AMD Helios rack-scale systems. The company continues to expand its AI capabilities through software development and planned acquisitions including World Labs and Taalas.

For the fourth quarter, AMD expects revenue of approximately $17 billion, plus or minus 3%. The midpoint implies roughly 66% year-over-year growth and a 27% sequential increase, signaling a significant acceleration from the already strong third quarter. Non-GAAP gross margin is expected at approximately 55%.

The 8% premarket gain appears to reflect the combination of exceptional Data Center growth, expanding operating margins and an unusually strong Q4 revenue outlook. With Data Center now accounting for the majority of quarterly revenue and management forecasting another sharp sequential increase, investors are increasingly treating AMD’s AI accelerator and server CPU businesses as the central drivers of its growth trajectory.
Post Image
AMD Expands Meta AI Partnership as Helios Systems Enter Deployment

AMD (NASDAQ: AMD) said it is expanding its strategic partnership with Meta across CPUs, GPUs, networking, systems and software as the two companies scale infrastructure for Meta’s AI and superintelligence workloads.

Initial AMD Helios rack-scale systems have been installed and are being tested by Meta ahead of a broader deployment. AMD EPYC processors already support Meta’s Muse AI agent, while Meta has deployed millions of EPYC CPUs across multiple generations and is a lead customer for sixth-generation EPYC processors.

AMD Instinct GPUs are also being used in production for training, ranking and recommendation workloads. Meta was an early definition customer for the MI450 architecture and plans to deploy a custom Instinct GPU optimized for its workloads. The collaboration is also influencing future AMD platforms, including the MI500 series and next-generation rack-scale systems.

On the software side, AMD and Meta are working together on ROCm, PyTorch and Triton, including optimization of large-scale AI training on MI350X GPUs. AMD also said its hardware provides Day-0 support for Meta models including Muse Spark Open and Muse Glimmer.

The companies said they are aligning future silicon, software and system roadmaps around Meta workloads, with the goal of building integrated AI infrastructure at gigawatt scale. AMD will also invest $1 billion in Meta’s equity offering.

The announcement strengthens AMD’s position as a supplier to one of the world’s largest AI infrastructure buyers and expands its role beyond individual processors into full rack-scale systems, networking and software.
Post Image
AMD Gains as Citi Lifts Price Target to $800, Mizuho Raises Target to $705

Advanced Micro Devices (NASDAQ: AMD) shares rose about 2.7% on Tuesday after analysts issued bullish updates tied to the company’s expanding role in AI infrastructure and server CPUs.

Citi analyst Atif Malik reiterated a Buy rating on AMD and raised his price target to $800 from $575. Malik said Meta’s newly launched Muse AI agent could significantly increase compute demand and strengthen AMD’s position in the server CPU market.

Citi now estimates the CPU total addressable market could grow from $29 billion in 2025 to $300 billion by 2030, implying a roughly 60% compound annual growth rate.

Malik expects AMD to be the primary beneficiary of what he described as a “CPU renaissance,” with Meta viewed as one of AMD’s largest server customers. He also argued that agentic AI could require orders of magnitude more computing power than traditional chatbot workloads (yahoofinance).

Mizuho also became more bullish on AMD, with analyst Vijay Rakesh raising the firm’s price target to $705 from $580 while maintaining an Outperform rating.

The analyst optimism follows a strong run of fundamental catalysts for AMD. The company recently reported record second-quarter revenue of $11.5 billion, up 50% year over year, while Data Center revenue more than doubled to $6.7 billion on strong demand for EPYC server processors and Instinct AI accelerators (yahoofinance).

AMD is also preparing its next generation of AI hardware, including the Instinct MI450 GPUs, 6th Gen EPYC Venice CPUs and Helios rack-scale AI systems.

The combination of higher analyst price targets, expectations for rapidly expanding AI-driven CPU demand and continued strength in AMD’s data center business appears to be supporting the stock’s latest move higher.
Post Image
AMD Rose 2.2% After Piper Sandler Initiated Coverage With $600 Target

Advanced Micro Devices (NASDAQ: AMD) shares rose 2.2% yesterday after Piper Sandler initiated coverage of the chipmaker with an Overweight rating and a $600 price target.

AMD has built a strong position in the rapidly expanding AI and data-center market through its Instinct accelerators, EPYC server processors and increasingly complete rack-scale AI infrastructure. Data Center revenue more than doubled year over year to $6.7 billion in the second quarter, driven by strong demand for EPYC processors and Instinct MI350-series GPUs.

The company is also expanding its position in large-scale AI infrastructure. Its latest portfolio includes the MI400-series accelerators, sixth-generation EPYC CPUs and Helios rack-scale systems, giving AMD exposure across AI training, inference and agentic workloads. Major AI and cloud customers working with AMD technology include OpenAI, Meta, Microsoft and Anthropic.

AMD’s combination of accelerating data-center growth, a broader AI product portfolio and expanding hyperscale deployments provides a strong fundamental backdrop as the company competes for a larger share of global AI infrastructure spending.
Post Image
AMD Stock Rises 3.5% as CLSA Reiterates Outperform Rating With $710 Price Target

Advanced Micro Devices (NASDAQ: AMD) shares rose 3.5% to $523.37 on Wednesday as CLSA reiterated its Outperform rating on the semiconductor company.

CLSA maintained a $710 price target on AMD, implying approximately 36% upside from the stock price shown.

The reiterated bullish rating comes as AMD remains a major beneficiary of growing investment in artificial intelligence infrastructure, with investors closely watching the company’s ability to expand its position in the AI accelerator market.

AMD shares have attracted strong investor attention as the company competes for a larger share of AI computing demand while continuing to expand its data center processor business.
Video Thumbnail
11-19-26The Investor
Video Thumbnail
11-16-26WS News
Video Thumbnail
11-12-26WS Investor
Video Thumbnail
11-12-26WS Investor
Video Thumbnail
11-11-26The Investor

NYSE:WSM

Williams-Sonoma Falls 7.2% Premarket as Reiterated Outlook Disappoints Despite Strong Q3

Williams-Sonoma (NYSE: WSM) shares fell 7.2% in premarket trading despite reporting solid third-quarter sales growth, margin expansion and double-digit adjusted EPS growth.

Comparable brand revenue increased 5.1%, while net revenue rose 5.8%. Non-GAAP operating margin improved 40 basis points to 17.4%, and adjusted diluted EPS increased 11.7% to $2.19. Every brand and channel posted positive comparable growth.

Underlying profitability remained strong, but some of the headline margin improvement came from tariff refunds. GAAP gross margin expanded 150 basis points, including a 140-basis-point benefit from IEEPA tariff refunds, while the non-GAAP gross margin increased only 10 basis points. Inventory also rose 7.3%, faster than revenue.

The 7.2% premarket decline appears to reflect disappointment that Williams-Sonoma merely reiterated its full-year outlook despite the strong quarter. Investors may also be focusing on elevated inventory, higher supply-chain costs and the limited underlying gross-margin expansion once tariff benefits are excluded. The company continues to expect fiscal 2026 revenue growth of 4.7%-7.2%, comparable growth of 4.0%-6.5% and a non-GAAP operating margin of 17.8%-18.2%.
Williams-Sonoma Stock Falls 2% Despite Strong Q2 Results and Raised 2026 Outlook

Williams-Sonoma (NYSE: WSM) shares fell about 2% on Wednesday even after the home furnishings retailer reported strong second-quarter fiscal 2026 results and raised its full-year outlook.

The decline appears to reflect investor concerns over underlying margin pressure and the quality of the earnings beat, as a significant portion of the company's GAAP profit improvement came from one-time tariff refunds.

Sales Growth Remains Strong

Williams-Sonoma reported comparable brand revenue growth of 6.2%, while total revenue increased 6.7% year over year. Management said every brand delivered growth during the quarter and that the company continued to gain market share despite a challenging housing environment.

Non-GAAP diluted EPS rose 5% to $2.10, while non-GAAP operating income reached $338 million. The company maintained $1.0 billion in cash and generated $696 million in operating cash flow.

However, underlying profitability showed some pressure. Non-GAAP gross margin declined 160 basis points year over year to 45.5%, primarily because merchandise margin fell 230 basis points due to tariff costs. Non-GAAP operating margin declined 60 basis points to 17.3%.

Tariff Refunds Boost GAAP Earnings

The headline GAAP numbers were considerably stronger, with operating margin reaching 22.9% and diluted EPS jumping 42% to $2.84.

But these figures benefited substantially from tariff-related items. Williams-Sonoma recognized $167.8 million in reductions to cost of goods sold from refunds of previously paid IEEPA tariffs, partially offset by vendor reimbursements and a $10 million employee recognition expense.

The company therefore excluded these items from its non-GAAP results, making the adjusted figures a better indication of underlying operating performance.

Williams-Sonoma Raises 2026 Guidance

Williams-Sonoma nevertheless increased its full-year expectations. The company now forecasts fiscal 2026 net revenue growth of 4.7% to 7.2%, comparable revenue growth of 4.0% to 6.5%, and a non-GAAP operating margin of 17.8% to 18.2%.

The outlook assumes existing tariffs remain in place and oil prices stay elevated for the rest of the year.

The roughly 2% decline in WSM shares therefore appears less about weak demand and more about investors looking beneath the headline earnings numbers. Strong sales growth and higher guidance were positives, but declining underlying merchandise margins and continued tariff pressure may be limiting enthusiasm after the report.
Williams-Sonoma Stock Rises in Premarket After Piper Sandler Initiates Coverage With Overweight Rating

Williams-Sonoma (NYSE: WSM) shares gained 2.2% in premarket trading on Monday after Piper Sandler initiated coverage of the home furnishings retailer with an Overweight rating.

The analyst initiation reflects confidence in Williams-Sonoma's ability to sustain earnings growth despite a challenging consumer spending environment. The company has continued to benefit from its portfolio of premium brands, including Pottery Barn, West Elm, and Williams Sonoma, as well as its strong e-commerce platform and disciplined inventory management.

Piper Sandler's bullish stance comes as investors increasingly favor retailers with resilient margins, healthy cash generation, and loyal customer bases. Williams-Sonoma has consistently outperformed many peers through effective pricing strategies, operational efficiency, and a capital-light business model that has supported profitability even as discretionary spending has moderated.

The positive analyst action also follows improving sentiment toward the retail sector, supported by expectations that lower U.S. interest rates could help boost housing activity and consumer demand for home-related products over time.

Looking ahead, investors will focus on Williams-Sonoma's upcoming earnings report for updates on comparable sales, consumer demand trends, and margin performance. Any signs of a recovery in the housing market or discretionary spending could provide additional support for the stock in the coming quarters.
Williams-Sonoma Rises 2% as Consistent Execution and Margin Resilience Reassure Investors

Williams-Sonoma edged up 2% after the premium home furnishings retailer delivered a first quarter that demonstrated the kind of steady, reliable performance that has become its trademark — every brand positive, margins holding firm and full-year guidance reiterated with confidence.

Total comparable brand revenue grew 4.8% in Q1, with every brand in the portfolio delivering positive comps. Operating income came in at $292 million with an operating margin of 16.2%, down just 60 basis points from a year ago. Diluted EPS grew 4.3% to $1.93. The company generated $156 million in operating cash flow and returned $373 million to shareholders through $288 million in buybacks and $85 million in dividends, all while maintaining a liquidity position of $652 million in cash.

The margin story deserves careful reading in the context of the current tariff environment. Gross margin of 44.0% declined 30 basis points year over year, reflecting lower merchandise margins of 100 basis points weighed down by tariff costs, partially offset by 50 basis points of supply chain efficiencies and 20 basis points of occupancy leverage. Merchandise inventories rose 9.0% to $1.46 billion, explicitly including approximately $60 million in incremental tariff costs — a figure that illustrates the real cost pressure the business is absorbing while still delivering positive comparable sales growth.

CEO Laura Alber's commentary was notably confident, pointing to compounding results year after year despite housing market cyclicality and macroeconomic headwinds. Full-year guidance was reiterated at comparable revenue growth of 2.0% to 6.0% and operating margin of 17.5% to 18.1% — a range that explicitly assumes elevated oil prices, no tariff refunds and all current tariff rates remaining in place for the full year.

The 2% gain reflects a market that found reassurance in a company that is not hiding from the tariff reality but rather building it into its assumptions and still delivering solid results. In a week where Walmart fell 7% and Target dropped 6.5% partly on margin concerns, Williams-Sonoma's ability to hold margin while absorbing tariff costs and grow comps across every brand was a genuinely differentiated message.

Three Brand Name Companies Outside Of Tech That Are On The Move

Last week’s push to new highs in the market continued...

(articles.stockcharts.com)
Williams-Sonoma Reports Strong Q1 2025 Results, Reaffirms Full-Year Outlook Despite Tariff Headwinds

Williams-Sonoma, Inc. (NYSE: WSM) announced solid first quarter fiscal 2025 results, with strong profitability and better-than-expected revenue growth, while reaffirming its full-year guidance.

Q1 2025 Highlights:
• Comparable brand revenue growth: +3.4%
• Net revenues: $1.73 billion, up 4.2% year-over-year
• Operating margin: 16.8%
• Diluted EPS: $1.85 (up 8.8% excluding a prior year freight adjustment)
• SG&A expenses: $475 million, or 27.5% of revenues (down 130bps from last year)
• Gross margin: 44.3% (adjusted -60bps YOY after excluding a prior year adjustment)
• Net income: $231 million
• Merchandise inventories: Up 10.3% to $1.3 billion, strategically pulled forward due to tariff concerns
• Cash position: $1.05 billion, despite $165 million returned to shareholders through buybacks and dividends

Brand Performance (Comparable Revenue Growth):
• Williams Sonoma: +7.3%
• Pottery Barn Kids and Teen: +3.8%
• Pottery Barn: +2.0%
• West Elm: +0.2%
• Total: +3.4%
Outlook:
• Full-year FY25 guidance reaffirmed:
o Net revenue range: -1.5% to +1.5%
o Comparable sales: flat to +3.0%
o Operating margin: 17.4% to 17.8%
• Guidance incorporates significant tariff impacts (30% on China, 25% on Mexico/Canada/steel/aluminum, 10% global reciprocal tariffs)
• Long-term goals remain unchanged: mid-to-high single-digit annual revenue growth and operating margins in the mid-to-high teens

Additional Notes:
• Q1 results include a retrospective adjustment from FY24 related to over-recognized freight expenses totaling $49 million, which impacted prior year comparables.
• A 2-for-1 stock split took effect on July 9, 2024; all share data reflects the split.
• The company ended Q1 with 508 stores, a net reduction of four locations during the quarter.

CEO Laura Alber cited strong performance across all brands and reaffirmed confidence in the company’s ability to adapt amid ongoing macroeconomic uncertainty.
Williams-Sonoma, Inc. reported strong fourth-quarter and fiscal year 2024 results, surpassing expectations in key financial metrics. The company achieved a 3.1% increase in comparable brand revenue for Q4, along with a record operating margin of 21.5% and diluted EPS of $3.28. For the full fiscal year, comparable brand revenue declined by 1.6%, but the company still delivered a record annual operating margin of 17.9% and full-year diluted EPS of $8.50.

CEO Laura Alber highlighted the company's focus on operational efficiency, strategic product launches, and robust demand in retail and online furniture sales. She expressed confidence in the company's strategies for 2025, emphasizing a return to growth, enhanced customer service, and strong earnings performance.

Q4 gross margin increased to 47.3%, benefiting from occupancy leverage (+80 bps), higher merchandise margins (+40 bps), and supply chain efficiencies (+10 bps). Operating income reached $530 million, up 140 basis points year-over-year, while SG&A expenses increased by 7.6%, primarily due to higher performance-based compensation and advertising. The additional week in Q4 2024 contributed approximately 5.1% to revenue growth and 60 basis points to operating margin.

For the full fiscal year, the company achieved an operating income of $1.43 billion and an operating margin of 18.6%, or 17.9% excluding a $49 million out-of-period freight adjustment recorded in Q1. The company maintained strong liquidity with $1.2 billion in cash and generated $1.4 billion in operating cash flow. It returned $1.1 billion to shareholders through $807 million in stock repurchases and $280 million in dividends. The board approved a 16% increase in the quarterly dividend, raising it to $0.66 per share.

Looking ahead to fiscal 2025, Williams-Sonoma expects net revenue growth between -1.5% and +1.5% due to the impact of an extra week in 2024. On a comparable 52-week basis, the company projects comps between flat and +3.0% and an operating margin between 17.4% and 17.8%. Over the long term, it continues to target mid-to-high single-digit annual net revenue growth with an operating margin in the mid-to-high teens.

During Q1 2024, the company corrected a historical over-accrual of freight expenses, resulting in a one-time adjustment of $49 million that benefited gross margin. In Q2, it also completed a 2-for-1 stock split.

Segment-wise, Q4 revenue growth was led by Williams Sonoma (+5.7%), West Elm (+4.2%), and Pottery Barn Kids and Teen (+3.5%), while Pottery Barn saw a slight decline (-0.5%). For the full year, Pottery Barn (-6.2%) and West Elm (-2.0%) reported declines, while Williams Sonoma (+2.4%) and Pottery Barn Kids and Teen (+3.0%) posted gains.

The company continues to focus on innovation, operational efficiencies, and strategic investments to drive long-term profitability while maintaining a disciplined approach to cost management and shareholder returns.
Video Thumbnail
11-19-26The Investor
Video Thumbnail
08-26-26The Investor
Video Thumbnail
06-03-26WS Investor
Video Thumbnail
03-13-25The Investor

NYSE:BBWI

Bath & Body Works Rises 2.6% as Q3 Beats Guidance and Full-Year Sales Outlook Improves

Bath & Body Works (NYSE: BBWI) shares rose 2.6% after the retailer reported third-quarter sales and adjusted earnings above its guidance and raised its full-year sales outlook.

Third-quarter net sales declined 1.0% to $1.58 billion, while adjusted EPS came in at $0.26. Adjusted operating income was $121 million, compared with $153 million a year earlier, showing that profitability remains under pressure even as sales trends improve.

Management highlighted continued progress in digital, product innovation and expanded distribution through Ulta and Amazon. The company also authorized a new $500 million share repurchase program, adding support to the shareholder-return story.

The 2.6% gain appears to reflect the better-than-guided quarter, improved sales outlook and new buyback authorization. Bath & Body Works now expects full-year sales to decline 3.4%-2.1%, an improvement from its prior view, while maintaining adjusted EPS guidance of $2.60-$2.80. However, the company still expects fourth-quarter sales to fall 5.5%-2.0%, indicating that the consumer backdrop remains challenging.
Bath & Body Works Rises 3.6% as Q2 Beats Guidance and Turnaround Shows Early Progress

Bath & Body Works (NYSE: BBWI) shares rose about 3.6% after the retailer reported fiscal second-quarter 2026 sales and earnings above its guidance and raised its full-year earnings outlook. The positive reaction comes despite continued sales pressure, suggesting investors are focusing on early signs that the company's turnaround strategy is beginning to gain traction.

Q2 Results Beat Expectations

Second-quarter net sales were $1.51 billion, down 2.3% year over year. While revenue remained under pressure, management said the result exceeded its guidance.

Adjusted EPS reached $0.62, compared with $0.37 a year earlier, while adjusted operating income increased to $225 million from $172 million.

However, the headline earnings improvement was heavily influenced by approximately $80 million of tariff refunds. Excluding that benefit, adjusted EPS would have been $0.31.

That distinction is important: the quarter was better than management expected, but the reported year-over-year earnings growth substantially overstates the improvement in the underlying business.

Turnaround Signals Support the Stock

The more encouraging development may be operational rather than purely financial.

Bath & Body Works reported its first quarter of direct net sales growth since 2021, which management attributed partly to improvements in its digital shopping experience. The company also cited sequential improvement in Body Care, stronger average unit retail on new product innovation and continued momentum through marketplace partnerships.

CEO Daniel Heaf said these developments provide early evidence that the company's "Consumer First Formula" strategy is working, although he acknowledged that underlying business trends remain pressured.

For investors, evidence that digital sales and key product categories are stabilizing could be particularly important after an extended period of weak growth.

Full-Year EPS Guidance Raised, But Sales Still Expected to Fall

Bath & Body Works raised fiscal 2026 GAAP EPS guidance to $3.13-$3.33 and adjusted EPS guidance to $2.60-$2.80. The company also expects approximately $650 million of free cash flow.

Sales guidance was narrowed to a decline of 2.5%-4%, indicating that management still expects revenue contraction for the year.

The near-term outlook also remains challenging. For Q3, sales are expected to decline 2.5%-5%, while adjusted EPS of $0.07-$0.12 would be substantially below $0.35 in the year-ago quarter.

The 3.6% rise in BBWI therefore appears to reflect a cautiously positive reaction rather than a clear return to growth. Q2 exceeded guidance, digital sales improved and management raised its earnings outlook, providing evidence that the transformation is making progress. Still, declining sales, weak Q3 earnings guidance and the large contribution from tariff refunds show that the underlying recovery remains at an early stage.
BBWI fell 12% today after Bath & Body Works reported first-quarter 2026 earnings that exceeded guidance but reinforced investor concerns about slowing sales growth, weak forward outlooks and ongoing uncertainty surrounding the retailer’s turnaround strategy.

The company posted first-quarter net sales of $1.38 billion, down 3% year over year, while reaffirming its full-year forecast for revenue to decline between 4.5% and 2.5%. Management also projected second-quarter sales to fall another 3% to 5%, signaling that demand pressures are expected to persist through much of 2026.

Although reported earnings per diluted share rose to $0.90 from $0.49 a year earlier, much of the improvement came from one-time items, including an $88 million pre-tax litigation settlement gain and a $62 million tax benefit. Excluding special items, adjusted EPS came in at just $0.32, reflecting ongoing pressure on the core business.

CEO Daniel Heaf acknowledged that while results exceeded guidance, performance still remains “below the standard our brand is capable of delivering.” The company said its “Consumer First Formula” turnaround plan is beginning to generate early positive signs through investments in hero product categories, brand modernization and customer engagement initiatives, but management made clear that meaningful improvement is expected to build gradually into 2027 rather than immediately.

Investors also appeared unsettled by the sudden departure of Chief Financial Officer Eva Boratto, who will step down in June. The company announced an interim CFO appointment while conducting a broader executive search, creating additional uncertainty at a time when Bath & Body Works is already navigating slowing sales and shifting consumer demand trends.

The market reaction suggests investors were hoping for stronger evidence of stabilization and a more optimistic near-term outlook. While Bath & Body Works maintained full-year earnings guidance and continues to generate solid cash flow, the retailer still faces a difficult environment marked by cautious consumer spending, promotional competition and pressure on discretionary retail categories.

The sharp selloff indicates investors remain skeptical that the company’s turnaround efforts will produce a meaningful acceleration in growth anytime soon, despite management’s confidence in the longer-term recovery strategy.
Bath & Body Works Appoints Daniel Heaf as CEO; Reports Strong Q1 2025 Results

Bath & Body Works, Inc. (NYSE: BBWI) announced the appointment of Daniel Heaf as Chief Executive Officer, effective immediately. Heaf, a seasoned leader with prior senior roles at Nike and Burberry, will also join the Board of Directors following the 2025 Annual Meeting. He replaces Gina Boswell, who has stepped down.

Heaf brings extensive experience in consumer and retail transformation. At Nike, he previously led the direct-to-consumer business to more than double in size and most recently served as Chief Strategy and Transformation Officer.

First Quarter 2025 Preliminary Results:
• Net Sales: $1.424 billion (up 3% year-over-year), meeting the high end of guidance.
• Earnings Per Share: $0.49, exceeding the high end of guidance.
• Full-Year Outlook Maintained: Sales growth of 1% to 3% and EPS of $3.25 to $3.60.
The company will hold its earnings call on May 29, 2025, at 8:30 a.m. ET.

Chair Sarah Nash praised Heaf as a bold, consumer-first leader with a clear vision to evolve the brand. Heaf emphasized Bath & Body Works’ potential to grow into a global home fragrance and beauty leader, citing the company’s strong foundation of brand loyalty and retail footprint.
Bath & Body Works, Inc. has announced that its Chief Executive Officer, Gina Boswell, will take a temporary leave of absence to undergo scheduled surgery. The absence is expected to last several weeks.
Bath & Body Works, Inc. has filed a Form 8-K with the SEC, reaffirming its financial guidance for the first quarter and full year of fiscal 2025. During its participation in the Bank of America Consumer & Retail Conference – Fireside Chat on March 11, 2025, the company reiterated its previously announced projections.

For the first quarter of 2025, the company expects net sales growth between 1% and 3% and earnings per diluted share in the range of $0.36 to $0.43. For the full fiscal year 2025, net sales growth is projected to be between 1% and 3%, with earnings per diluted share estimated between $3.25 and $3.60.

The company made this announcement in connection with its investor presentation, and the audio webcast of the event is available on the company's Investor Relations website. The information was furnished under Regulation FD and is not considered filed under the Exchange Act.
Bath & Body Works reported its fourth-quarter and full-year 2024 results, exceeding earnings expectations and providing 2025 guidance.

The company recorded fourth-quarter net sales of $2.8 billion and earnings per diluted share of $2.09, surpassing projections. Strong traffic and conversion rates contributed to performance, despite a 4.3% decline in sales due to a shifted fiscal calendar that included an extra week in 2023. Net income for the quarter was $453 million, down from $579 million in the prior year.

For the full year, net sales declined 1.6% to $7.3 billion, reflecting the impact of the 53rd week in fiscal 2023. Earnings per diluted share were $3.61, compared to $3.84 in 2023. The company repurchased 10.4 million shares for $400 million and exited the year with a debt leverage ratio of 2.5x.

Looking ahead to 2025, Bath & Body Works expects net sales growth of 1% to 3% and earnings per diluted share between $3.25 and $3.60. The first quarter is projected to see similar sales growth, with earnings per diluted share between $0.36 and $0.43. The company also authorized a new $500 million share repurchase program.

CEO Gina Boswell highlighted the company’s success in product innovation, marketing, and international expansion, positioning it for continued growth despite broader retail sector challenges.
Video Thumbnail
11-19-26The Investor